Exhibit 10.1

       

  

   
  
     Execution Version

  

   
   

     

   
  INSMED INCORPORATED

   
  Shares of Common Stock

   
  ($0.01 par value per share)

   
  

     

   
  SALES AGREEMENT

   
  

     

   
  February 25, 2021

   
  

     

   
  SVB LEERINK LLC

   
  1301 Avenue of the Americas, 12th Floor

   
  New York, New York 10019

   
  

     

   
  Ladies and Gentlemen:

   
  

     

   
  Insmed Incorporated, a Virginia corporation (the “Company”),



    confirms its agreement (this “Agreement”) with SVB Leerink LLC (the “Agent”),


    as follows:

   
  

     

   
  1.            Issuance and Sale of Shares.  The Company agrees that, from time to time during the term of this Agreement,
      on the terms and subject to the conditions set forth herein, it may issue and sell through the Agent up to $250,000,000 of shares of common stock, $0.01 par value per share, of the Company (the “Common Stock”), subject to the limitations set forth in Section 5(c) (the “Placement Shares”).
      Notwithstanding anything to the contrary contained herein, the parties hereto agree that compliance with the limitation set forth in this Section 1 on the aggregate gross sales price of Placement Shares that may be issued and sold under this
      Agreement from time to time shall be the sole responsibility of the Company, and that the Agent shall have no obligation in connection with such compliance.  The issuance and sale of Placement Shares through the Agent will be effected pursuant to the
      Registration Statement (as defined below) filed by the Company with the Securities and Exchange Commission (the “Commission”) on May 21, 2020, which became
      automatically effective upon filing thereof pursuant to Rule 462(e) of the Securities Act of 1933, as amended, and the rules and regulations thereunder (collectively, the “Securities


          Act”), although nothing in this Agreement shall be construed as requiring the Company to issue any Placement Shares.

   
  

     

   
  The Company has prepared and filed, in accordance with the provisions of the Securities Act, with the Commission a registration statement
    on Form S-3ASR (File No. 333-238560), including a base prospectus, relating to certain securities, including the Common Stock, to be issued from time to time by the Company, and which incorporates by reference documents that the Company has filed or
    will file in accordance with the provisions of the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder (collectively, the “Exchange Act”).


    The Company has prepared a prospectus supplement to the base prospectus included as part of such registration statement at the time the registration statement became effective, which prospectus supplement specifically relates to the Placement Shares to
    be issued from time to time pursuant to this Agreement (the “Prospectus Supplement”). The Company will furnish to the Agent, for use by the Agent, copies of the
    base prospectus included as part of such registration statement at the time it became effective, as supplemented by the Prospectus Supplement. Except where the context otherwise requires, such registration statement, including all documents filed as
    part thereof or incorporated by reference therein, and including any information contained in a Prospectus (as defined below) subsequently filed with the Commission pursuant to Rule 424(b) under the Securities Act or deemed to be a part of such
    registration statement pursuant to Rule 430B or Rule 462(b) under the Securities Act, is herein called the “Registration Statement.” The base prospectus,
    including all documents incorporated therein by reference, included in the Registration Statement, as it may be supplemented by the Prospectus Supplement, in the form in which such prospectus and/or Prospectus Supplement have most recently been filed
    by the Company with the Commission pursuant to Rule 424(b) under the Securities Act, together with any “issuer free writing prospectus” (as used herein, as defined in Rule 433 under the Securities Act (“Rule 433”)), relating to the Placement Shares that (i) is required to be filed with the Commission by the Company or (ii) is exempt from filing pursuant to Rule 433(d)(5)(i), in each case, in the
    form filed or required to be filed with the Commission or, if not required to be filed, in the form retained in the Company’s records pursuant to Rule 433(g), is herein called the “Prospectus.”

   
  

     

   
  
    
      


  

  Any reference herein to the Registration Statement, the Prospectus Supplement, the Prospectus or any issuer free writing prospectus shall
    be deemed to refer to and include the documents, if any, that are or are deemed to be incorporated by reference therein (the “Incorporated Documents”),
    including, unless the context otherwise requires, the documents, if any, filed as exhibits to such Incorporated Documents. Any reference herein to the terms “amend,” “amendment” or “supplement” with respect to the Registration Statement, the Prospectus
    Supplement, the Prospectus or any issuer free writing prospectus shall be deemed to refer to and include the filing of any document under the Exchange Act on or after the most-recent effective date of the Registration Statement, or the respective dates
    of the Prospectus Supplement, Prospectus or such issuer free writing prospectus, as the case may be, and incorporated therein by reference. For purposes of this Agreement, all references to the Registration Statement, the Prospectus or any amendment or
    supplement thereto shall be deemed to include the most recent copy filed with the Commission pursuant to its Electronic Data Gathering Analysis and Retrieval System or, if applicable, the Interactive Data Electronic Application system when used by the
    Commission (collectively, “EDGAR”).

   
  

     

   
  2.            Placements.  Each time that the Company wishes to issue and sell any Placement Shares through the Agent
      hereunder (each, a “Placement”), it will notify the Agent by email notice (or other method mutually agreed to in writing by the parties) (each such notice, a “Placement Notice”) containing the parameters in accordance with which it desires such Placement Shares to be sold, which at a minimum shall include the maximum
      number or amount of Placement Shares to be sold, the time period during which sales are requested to be made, any limitation on the number or amount of Placement Shares that may be sold in any one Trading Day (as defined in Section 3) and any minimum
      price below which sales may not be made, a form of which containing such minimum sales parameters is attached hereto as Schedule 1.  The Placement Notice must
      originate from one of the individuals authorized to act on behalf of the Company and set forth on Schedule 2 (with a copy to each of the other individuals
      from the Company listed on such Schedule 2), and shall be addressed to each of the recipients from the Agent set forth on Schedule 2, as such Schedule 2 may be updated by either party from time to time by sending a
      written notice containing a revised Schedule 2 to the other party in the manner provided in Section 12 (including by email correspondence to each of the
      individuals of the Company set forth on Schedule 2, if receipt of such correspondence is actually acknowledged by any of the individuals to whom the notice is
      sent, other than via auto-reply). The Placement Notice shall be effective upon receipt by the Agent unless and until (i) in accordance with the notice requirements set forth in Section 4, the Agent declines to accept the terms contained therein for
      any reason, in its sole discretion, within two Trading Days of the date the Agent receives the Placement Notice, (ii) in accordance with the notice requirements set forth in Section 4, the Agent suspends sales under the Placement Notice for any
      reason in its sole discretion, (iii) the entire amount of the Placement Shares has been sold pursuant to this Agreement, (iv) in accordance with the notice requirements set forth in Section 4, the Company suspends sales under or terminates the
      Placement Notice for any reason in its sole discretion, (v) the Company issues a subsequent Placement Notice and explicitly indicates that its parameters supersede those contained in the earlier dated Placement Notice or (vi) this Agreement has been
      terminated pursuant to the provisions of Section 11. The amount of any discount, commission or other compensation to be paid by the Company to the Agent in connection with the sale of the Placement Shares effected through the Agent shall be
      calculated in accordance with the terms set forth in Schedule 3.  It is expressly acknowledged and agreed that neither the Company nor the Agent will have any
      obligation whatsoever with respect to a Placement or any Placement Shares unless and until the Company delivers a Placement Notice to the Agent and the Agent does not decline such Placement Notice pursuant to the terms set forth above, and then only
      upon the terms specified therein and herein. In the event of a conflict between the terms of this Agreement and the terms of a Placement Notice, the terms of the Placement Notice will control with respect to the matters covered thereby.

   
  

     

   
  
    
      


  

  3.            Sale of Placement Shares by the Agent.  On the basis of the representations and warranties herein contained
      and subject to the terms and conditions herein set forth, including Section 5(c), upon the Agent’s acceptance of the terms of a Placement Notice as provided in Section 2, and unless the sale of the Placement Shares described therein has been
      declined, suspended or otherwise terminated in accordance with the terms of this Agreement, the Agent, for the period specified in the Placement Notice, will use its commercially reasonable efforts consistent with its normal trading and sales
      practices and applicable state and federal laws, rules and regulations and the rules of the Nasdaq Global Select Market (“Nasdaq”) to sell such Placement
      Shares up to the number or amount specified in, and otherwise in accordance with the terms of, such Placement Notice.  The Agent shall not sell Placement Shares other than in accordance with the terms of the applicable Placement Notice and this
      Agreement.  The Agent will provide written confirmation to the Company (including by email correspondence to each of the individuals of the Company set forth on Schedule
          2, if receipt of such correspondence is actually acknowledged by any of the individuals to whom the notice is sent, other than via auto-reply) no later than the opening of the Trading Day (as defined below) immediately following the
      Trading Day on which it has made sales of Placement Shares hereunder setting forth the number or amount of Placement Shares sold on such Trading Day, the volume-weighted average price of the Placement Shares sold and the Net Proceeds (as defined
      below) payable to the Company.  Unless otherwise specified by the Company in a Placement Notice, the Agent may sell Placement Shares by any method permitted by law deemed to be an “at the market offering” as defined in Rule 415 of the Securities Act,
      including sales made directly on or through Nasdaq, on or through any other existing trading market for the Common Stock or to or through a market maker. If expressly authorized by the Company (including in a Placement Notice), the Agent may also
      sell Placement Shares in negotiated transactions. Notwithstanding the provisions of Section 6(oo), except as may be otherwise agreed by the Company and the Agent, the Agent shall not purchase Placement Shares on a principal basis pursuant to this
      Agreement unless the Company and the Agent enter into a separate written agreement setting forth the terms of such sale. The Company acknowledges and agrees that (i) there can be no assurance that the Agent will be successful in selling Placement
      Shares, (ii) the Agent will incur no liability or obligation to the Company or any other person or entity if it does not sell Placement Shares for any reason other than a failure by the Agent to use its commercially reasonable efforts consistent with
      its normal trading and sales practices and applicable state and federal laws, rules and regulations and the rules of Nasdaq to sell such Placement Shares as required under this Agreement and (iii) the Agent shall be under no obligation to purchase
      Placement Shares on a principal basis pursuant to this Agreement unless the Company and the Agent enter into a separate written agreement setting forth the terms of such sale. For the purposes hereof, “Trading Day” means any day on which the Common Stock is purchased and sold on Nasdaq.

   
  

     

   
  
    
      


  

  4.            Suspension of Sales.

   
  

     

   
  (a)            The Company or the Agent may, upon notice to the other party in writing (including by email correspondence to each of the individuals of the other party set forth on Schedule 2, if receipt of such correspondence is actually acknowledged by any of the individuals to whom the notice is sent, other than via auto-reply) or by
      telephone (confirmed immediately by email correspondence to each of the individuals of the other party set forth on Schedule 2), suspend any sale of Placement
      Shares; provided, however, that such suspension shall not affect or impair
      either party’s obligations with respect to any Placement Shares sold hereunder prior to the receipt of such notice.  Each of the parties agrees that no such notice under this Section 4 shall be effective against the other party unless notice is sent
      by one of the individuals named on Schedule 2 hereto to the other party in writing (including by email correspondence to each of the individuals of the other
      party set forth on Schedule 2, if receipt of such correspondence is actually acknowledged by any of the individuals to whom the notice is sent, other than via
      auto-reply).

   
  

     

   
  (b)            Notwithstanding any other provision of this Agreement, during any period in which the Company is in possession of material non-public information, the Company and the Agent agree
      that (i) no sale of Placement Shares will take place, (ii) the Company shall not request the sale of any Placement Shares and shall cancel any effective Placement Notices instructing the Agent to make any sales and (iii) the Agent shall not be
      obligated to sell or offer to sell any Placement Shares.

   
  

     

   
  5.            Settlement and Delivery of the Placement Shares.

   
  

     

   
  (a)            Settlement of Placement Shares.  Unless otherwise specified in the applicable Placement Notice, settlement
      for sales of Placement Shares will occur on the second Trading Day (or such earlier day as is industry practice or as is required for regular-way trading) following the date on which such sales are made (each, a “Settlement Date”).  The amount of proceeds to be delivered to the Company on a Settlement Date against receipt of the Placement Shares sold (the “Net Proceeds”) will be equal to the aggregate gross sales price received by the Agent at which such Placement Shares were sold, after deduction of (i) the Agent’s commission, discount or other
      compensation for such sales payable by the Company pursuant to Section 2 hereof, (ii) any other amounts due and payable by the Company to the Agent hereunder pursuant to Section 7(g) hereof and (iii) any transaction fees imposed by any governmental
      or self-regulatory organization in respect of such sales.

   
  

     

   
  (b)            Delivery of Placement Shares.  On or before each Settlement Date, the Company will issue the Placement
      Shares being sold on such date in accordance with this Agreement and will, or will cause its transfer agent to, electronically transfer such Placement Shares by crediting the Agent’s or its designee’s account (provided the Agent shall have given the
      Company written notice of such designee prior to the Settlement Date) at The Depository Trust Company through its Deposit and Withdrawal at Custodian System (“DWAC”)


      or by such other means of delivery as may be mutually agreed upon by the parties hereto, which in all cases shall be duly authorized, freely tradeable, transferable, registered shares of Common Stock. On each Settlement Date, the Agent will deliver
      the related Net Proceeds in same day funds to an account designated by the Company on or prior to the Settlement Date. The Agent shall be responsible for providing DWAC instructions or other instructions for delivery by other means with regard to the
      transfer of the Placement Shares being sold. In addition to and in no way limiting the rights and obligations set forth in Section 9(a) hereto, the Company agrees that, in connection with sales of Placement Shares made by the Agent in accordance with
      this Agreement, if the Company or its transfer agent (if applicable), defaults in its obligation to deliver duly authorized, freely tradeable, transferable, registered Placement Shares by 2:30 P.M., New York City time, on a Settlement Date (other
      than as a result of a failure by the Agent to provide instructions for delivery), the Company will (i) take all necessary action to cause the full amount of any Net Proceeds that were delivered to the Company’s account with respect to such
      settlement, together with any costs incurred by the Agent and/or its clearing firm in connection with recovering such Net Proceeds, to be returned to the Agent or its clearing firm no later than 5:00 P.M., New York City time, on such Settlement Date,
      by wire transfer of immediately available funds to an account designated by the Agent or its clearing firm, (ii) indemnify and hold the Agent and its clearing firm harmless against any loss, claim, damage, or expense (including reasonable legal fees
      and expenses), as incurred, arising out of or in connection with such default by the Company or its transfer agent (if applicable) and (iii) pay to the Agent any commission, discount or other compensation to which it would otherwise have been
      entitled absent such default. Certificates for the Placement Shares, if any, shall be in such denominations and registered in such names as the Agent may request in writing the second Business Day (as defined below) before the applicable Settlement
      Date. Certificates for the Placement Shares, if any, will be made available by the Company for examination and packaging by the Agent in New York City not later than 12:00 P.M., New York City time, on the Business Day prior to the applicable
      Settlement Date.

   
  

     

   
  
    
      


  

  (c)            Limitations on Offering Size. Under no circumstances shall the Company cause or request the offer or sale
      of any Placement Shares if, after giving effect to the sale of such Placement Shares, the aggregate number or gross sales proceeds of Placement Shares sold pursuant to this Agreement would exceed the least of: (i) the number or dollar amount of
      shares of Common Stock registered pursuant to, and available for offer and sale under, the Registration Statement pursuant to which the offering of Placement Shares is being made, (ii) the number of authorized but unissued shares of Common Stock of
      the Company (less shares of Common Stock issuable upon exercise, conversion or exchange of any outstanding securities of the Company or otherwise reserved from the Company’s authorized capital stock), (iii) the number or dollar amount of shares of
      Common Stock permitted to be offered and sold by the Company under Form S-3 (including General Instruction I.B.6. thereof, if such instruction is applicable), (iv) the number or dollar amount of shares of Common Stock that the Company’s board of
      directors or a duly authorized committee thereof is authorized to issue and sell from time to time, and notified to the Agent in writing, and (v) the dollar amount of shares of Common Stock for which the Company has filed the Prospectus Supplement. 
      Under no circumstances shall the Company cause or request the offer or sale of any Placement Shares pursuant to this Agreement at a price lower than the minimum price authorized from time to time by the Company’s board of directors or a duly
      authorized committee thereof, and notified to the Agent in writing. Notwithstanding anything to the contrary contained herein, the parties hereto acknowledge and agree that compliance with the limitations set forth in this Section 5(c) on the number
      or dollar amount of Placement Shares that may be issued and sold under this Agreement from time to time shall be the sole responsibility of the Company, and that the Agent shall have no obligation in connection with such compliance.

   
  

     

   
  6.            Representations and Warranties of the Company.  The Company represents and warrants to, and agrees with,
      the Agent that as of the date of this Agreement, and as of (i) each Representation Date (as defined in Section 7(l), (ii) each date on which a Placement Notice is given, (iii) the date and time of each sale of any Placement Shares pursuant to this
      Agreement and (iv) each Settlement Date (each such time or date referred to in clauses (i) through (iv), an “Applicable Time”):

   
  

     

   
  (a)            The Company and the transactions contemplated by this Agreement meet the requirements for and comply with the conditions for the use of Form S-3 (including General Instructions
      I.A and I.B.1.) under the Securities Act. The Company has prepared and filed with the Commission an “automatic shelf registration statement” as defined in Rule 405 under the Securities Act on Form S-3, and the Placement Shares have been and remain
      eligible for registration by the Company on such automatic shelf registration statement. The Registration Statement meets, and the offering and sale of Placement Shares as contemplated hereby comply with, the requirements of Rule 415(a)(1)(x) under
      the Securities Act. The Agent is named as the agent engaged by the Company in the section entitled “Plan of Distribution” in the Prospectus Supplement. The Company has not received, and has no notice from the Commission of, any notice pursuant to
      Rule 401(g)(2) under the Securities Act objecting to the use of the shelf registration statement form. No stop order of the Commission preventing or suspending the use of the base prospectus, the Prospectus Supplement or the Prospectus, or the
      effectiveness of the Registration Statement, has been issued, and no proceedings for such purpose are pending before or, to the knowledge of the Company, threatened by the Commission. The Company has paid the registration fee for this offering
      pursuant to Rule 456(b)(1) under the Securities Act or will pay such fee within the time period required by such rule and in any event prior to delivery to the Agent of the first Placement Notice. Copies of the Registration Statement, the Prospectus,
      any such amendments or supplements to any of the foregoing and all Incorporated Documents that were filed with the Commission on or prior to the date of this Agreement are available through EDGAR, to the Agent and its counsel.

   
  

     

   
  
    
      


  

  (b)            Each of the Registration Statement and any post-effective amendment thereto, at the time it became or becomes effective, at each deemed effective date with respect to the Agent
      pursuant to Rule 430B(f)(2) under the Securities Act and as of each Applicable Time, complied, complies and will comply in all material respects with the requirements of the Securities Act and did not, does not and will not contain any untrue
      statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading, except that the representations and warranties set forth in this sentence do not apply to Agent’s
      Information (as defined below). The Prospectus and any amendment or supplement thereto, when so filed with the Commission under Rule 424(b) under the Securities Act, complied, complies and as of each Applicable Time will comply in all material
      respects with the requirements of the Securities Act, and each Prospectus Supplement, Prospectus or issuer free writing prospectus (or any amendments or supplements to any of the foregoing) furnished to the Agent for use in connection with the
      offering of the Placement Shares was identical to the electronically transmitted copies thereof filed with the Commission pursuant to EDGAR, except to the extent permitted by Regulation S-T. Neither the Prospectus nor any amendment or supplement
      thereto, as of its date and as of each Applicable Time, included, includes or will include an untrue statement of a material fact or omitted, omits or will omit to state a material fact necessary in order to make the statements therein, in the light
      of the circumstances under which they were made, not misleading, except that the representations and warranties set forth in this sentence do not apply to Agent’s Information. Each Incorporated Document heretofore filed, when it was filed (or, if any
      amendment with respect to any such document was filed, when such amendment was filed), complied in all material respects with the requirements of the Exchange Act, and any further Incorporated Documents so filed and incorporated after the date of
      this Agreement, when so filed, will comply in all material respects with the requirements of the Exchange Act.

   
  

     

   
  (c)            (i) At the time of filing the Registration Statement and (ii) at the time of the execution of this Agreement (with such date being used as the determination date for purposes of
      this clause (ii)), the Company was not and is not an “ineligible issuer” (as defined in Rule 405).

   
  
    

       

                   (d)            Any
        issuer free writing prospectus that the Company is required to file pursuant to Rule 433 under the Securities Act has been, or will be, filed with the Commission in accordance with the requirements of the Securities Act and the applicable rules and
        regulations of the Commission thereunder. Each issuer free writing prospectus that the Company has filed, or is required to file, pursuant to Rule 433 under the Securities Act or that was prepared by or on behalf of or used or referred to by the
        Company (x) complies or will comply in all material respects with the requirements of the Securities Act and the applicable rules and regulations of the Commission thereunder and (y) does not include any information that conflicts with the information contained in the Registration Statement, including any document incorporated therein by reference and any prospectus supplement deemed to be a
    part thereof that has not been superseded or modified.   

  

     

   
  (e)            The Company has not distributed and, prior to the later to occur of each Settlement Date and completion of the Agent’s distribution of the Placement Shares under this Agreement,
      will not distribute any written communication (as defined in Rule 405 under the Securities Act), that constitutes an offer to sell or solicitation of an offer to buy Placement Shares hereunder, other than the Registration Statement, the Prospectus or
      any Permitted Free Writing Prospectus (as defined below).

   
  

     

   
  (f)            Except for the Agent, there is no broker, finder or other financial advisor that is entitled to receive from the Company or any of its Subsidiaries (as defined below) any
      brokerage or finder’s fee or other fee or commission as a result of any transactions contemplated by this Agreement.

   
  

     

   
  
    
      


  

  (g)            The Company has been duly incorporated, is validly existing as a corporation in good standing under the laws of the jurisdiction of its incorporation, has the corporate power and
      authority to own its property and conduct its business as described in the Prospectus and is duly qualified to transact business and is in good standing in each jurisdiction in which the conduct of its business or ownership or leasing of the property
      requires such qualification, except to the extent that the failure to be so qualified or in good standing could not reasonably be expected, individually or in the aggregate, to have a material adverse effect on the Company and its Subsidiaries, taken
      as a whole.

   
  

     

   
  (h)            The Company’s only subsidiaries are as described in Exhibit 21.1 to the Company’s most recent Annual Report on Form 10-K filed with the Commission (each, a “Subsidiary” and collectively, the “Subsidiaries”).

   
  

     

   
  (i)            The authorized capital stock of the Company conforms as to legal matters to the description thereof contained in the Prospectus.

   
  

     

   
  (j)            The shares of Common Stock outstanding prior to the issuance of the Placement Shares have been duly authorized and are validly issued, fully paid and nonassessable.

   
  

     

   
  (k)            The Placement Shares have been duly authorized and, when issued and delivered by the Company in accordance with the terms of this Agreement, will be validly issued, fully paid and
      nonassessable, and the issuance of such Placement Shares will not be subject to any preemptive or similar rights, which have not otherwise been waived.

   
  

     

   
  (l)            There is no statute, regulation, contract or other document required to be described in the Registration Statement or the Prospectus or to be filed as an exhibit to the
      Registration Statement, which is not described or filed as required.

   
  

     

   
  (m)            This Agreement has been duly authorized, executed and delivered by the Company.

   
  

     

   
  (n)            The Company is not and, after giving effect to the offering and sale of the Placement Shares and the application of the proceeds thereof as described in the Prospectus, will not
      be required to be registered as an “investment company” as defined in the Investment Company Act of 1940, as amended.

   
  

     

   
  (o)            No consent, approval, authorization or order of, or qualification with, any governmental body or agency is required for the performance by the Company of its obligations under
      this Agreement, except such as may be required under the Securities Act or the rules and regulations thereunder or by the securities or Blue Sky laws of the various states or the rules and regulations of the Financial Industry Regulatory Authority (“FINRA”) in connection with the offer and sale of the Placement Shares.

   
  

     

   
  (p)            The execution and delivery by the Company of, and the performance by the Company of its obligations under, this Agreement will not contravene any provision of (i) applicable law,
      (ii) the articles of incorporation or bylaws of the Company, (iii) any agreement or other instrument binding upon the Company or any of its Subsidiaries or (iv) any judgment, order or decree of any governmental body, agency or court having
      jurisdiction over the Company or any Subsidiary, except in the cases of clauses (i), (iii) and (iv) for any such contravention that would not, singly or in the aggregate, have a material adverse effect on the Company and its Subsidiaries taken as a
      whole.

   
  

     

   
  
    
      


  

  (q)            Subsequent to the respective dates as of which information is given in the Registration Statement and the Prospectus: (i) there has not occurred any material adverse change, or
      any development involving a prospective material adverse change, in the condition, financial or otherwise, or in the earnings, business or operations of the Company and its Subsidiaries taken as a whole, (ii) the Company and its Subsidiaries have not
      incurred any material liability or obligation, direct or contingent, and have not entered into any material transactions, in each case, that would be required to be reported on a Current Report on Form 8-K, (iii) the Company has not purchased any of
      its outstanding capital stock, nor declared, paid or otherwise made any dividend or distribution of any kind on its capital stock, nor declared, paid or otherwise made any dividend or distribution of any kind on its capital stock other than ordinary
      and customary dividends and net settlements in connection with the Company’s existing employee compensation plans, and (iv) there has not been any material change in the short-term debt or long-term debt of the Company and its Subsidiaries, except in
      each case as described in each of the Registration Statement and the Prospectus, respectively.

   
  

     

   
  (r)            Except as described in the Prospectus, there are no contracts, agreements or understandings between the Company and any person granting such person the right to require the
      Company to file a registration statement under the Securities Act with respect to any securities of the Company or to require the Company to include such securities with the Placement Shares registered pursuant to the Registration Statement.

   
  

     

   
  (s)            There are no legal or governmental proceedings pending or to the knowledge of the Company, threatened to which the Company or any of its Subsidiaries is a party or to which any of
      the properties of the Company or any of its Subsidiaries is subject other than (i) proceedings accurately described in all material respects in the Prospectus or (ii) proceedings that would not reasonably be expected to have a material adverse effect
      on the Company and its Subsidiaries, taken as a whole, or on the power or ability of the Company to perform its obligations under this Agreement or to consummate the transactions contemplated by the Prospectus; and there are no statutes, regulations,
      contracts or other documents that are required to be described in the Registration Statement or the Prospectus or to be filed as exhibits to the Registration Statement that are not described or filed as required.

   
  

     

   
  (t)            The Company and its Subsidiaries do not own any real property. The Company and its Subsidiaries have good title to all personal property owned by them which is material to the
      business of the Company and its Subsidiaries, in each case free and clear of all liens, encumbrances and defects except such as are described in the Prospectus or such as do not materially affect the value of such property and do not interfere with
      the use made and proposed to be made of such property by the Company and its Subsidiaries; and any material real property and buildings held under lease by the Company and its Subsidiaries are held by them under valid, subsisting and enforceable
      leases with such exceptions as are not material and do not interfere with the use made and proposed to be made of such property and buildings by the Company and its Subsidiaries, in each case except as described in the Prospectus.

   
  

     

   
  (u)            The Company has filed all federal, state, local and foreign tax returns required to be filed through the date of this Agreement or has requested extensions thereof (except, in
      each case, where the failure to file would not, individually or in the aggregate, reasonably be expected to have a material adverse effect on the Company and its Subsidiaries, taken as a whole) and has paid all taxes required to be paid thereon
      (except for cases in which the failure to file or pay would not reasonably be expected to have a material adverse effect on the Company and its Subsidiaries, taken as a whole, or, except as currently being contested in good faith and for which
      reserves required by United States generally accepted accounting principles (“GAAP”) have been recorded in the financial statements of the Company), and there
      is no tax deficiency which if determined adversely to the Company would reasonably be expected to have (nor does the Company have any notice or knowledge of any tax deficiency which would reasonably be expected to be determined adversely to the
      Company and which would reasonably be expected to have) a material adverse effect on the Company and its Subsidiaries, taken as a whole.

   
  

     

   
  
    
      


  

  (v)            Except as described in the Prospectus, no material labor dispute with the employees of the Company or any of its Subsidiaries exists or, to the Company’s knowledge, is threatened
      or imminent, and the Company is not aware of any existing, threatened or imminent labor disturbance by the employees of any of its principal suppliers, manufacturers or contractors that could have a material adverse effect on the Company and its
      Subsidiaries, taken as a whole.

   
  

     

   
  (w)            The Company and each of its Subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and in such amounts as are prudent in the
      reasonable opinion of the Company’s management and customary in the businesses in which they are engaged; neither the Company nor any of its Subsidiaries has been refused any insurance coverage sought or applied for; and neither the Company nor any
      of its Subsidiaries has any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain comparable coverage from similar insurers as may be necessary to continue its business at a
      cost that would not reasonably be expected to have a material adverse effect on the Company and its Subsidiaries, taken as a whole, except as described in the Prospectus.

   
  

     

   
  (x)            Except as described in the Prospectus, (A) the Company and its Subsidiaries own or possess, or can acquire on reasonable terms, all material patents, patent rights, licenses,
      inventions, copyrights, know-how (including trade secrets and other unpatented and/or unpatentable proprietary or confidential information, systems or procedures), trademarks, service marks, trade names and other intellectual property (collectively,
      “Intellectual Property”) currently used and proposed to be used by them in connection with the Company’s business as now conducted and as described in the Prospectus,
      and (B) neither the Company nor any of its Subsidiaries has breached any material provision of any Intellectual Property license or received any notice of infringement of or conflict with asserted rights of others with respect to any of the
      foregoing, in the case of each of (A) and (B), which, singly or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would reasonably be expected to have a material adverse effect on the Company and its Subsidiaries, taken
      as a whole. There are no valid and enforceable rights of third parties to any Intellectual Property that are or would be infringed by the business currently conducted or planned to be conducted by the Company and its Subsidiaries or in the
      manufacture, use, sale or offer for sale of its presently proposed products, as such planned business and proposed products are described in the Prospectus which infringement, singly or in the aggregate, would reasonably be expected to have a
      material adverse effect on the Company and its Subsidiaries, taken as a whole. There are no pending patent applications of which the Company is aware, which, if granted in current form, would be infringed by the business currently conducted by it or
      proposed to be conducted by it as described in the Prospectus, which infringement, singly or in the aggregate, would reasonably be expected to have a material adverse effect on the Company and its Subsidiaries, taken as a whole. Neither the Company,
      nor any of its Subsidiaries, is subject to any judgment, order, writ, injunction or decree of any court or any federal, state, local, foreign or other governmental department, commission, board, bureau, agency or instrumentality, domestic or foreign,
      or any arbitrator, nor has it entered into or is it a party to any contract, in the case of each of the foregoing, which materially restricts or impairs its use of any Intellectual Property and which restriction or impairment, singly or in the
      aggregate, would reasonably be expected to have a material adverse effect on the Company and its Subsidiaries, taken as a whole. To the knowledge of the Company, there are no ongoing infringements by others of any Intellectual Property owned by the
      Company or its Subsidiaries in connection with the business currently conducted by the Company and its Subsidiaries or its presently proposed products, as described in the Prospectus, which infringement, singly or in the aggregate, would reasonably
      be expected to have a material adverse effect on the Company and its Subsidiaries, taken as a whole. The Company is not aware of any reason why any Intellectual Property owned or controlled by it is or should be held to be invalid or unenforceable,
      which holding, singly or in the aggregate, would reasonably be expected to have a material adverse effect on the Company and its Subsidiaries, taken as a whole.

   
  

     

   
  
    
      


  

  (y)            The Company and its Subsidiaries (i) are in compliance with any and all applicable foreign, federal, state and local laws and regulations relating to the protection of human
      health and safety, the environment or hazardous or toxic substances or wastes, pollutants or contaminants (“Environmental Laws”), (ii) have received all
      permits, licenses or other approvals required of them under applicable Environmental Laws to conduct their respective businesses and (iii) are in compliance with all terms and conditions of any such permit, license or approval, except where such
      noncompliance with Environmental Laws, failure to receive required permits, licenses or other approvals or failure to comply with the terms and conditions of such permits, licenses or approvals would not, singly or in the aggregate, have a material
      adverse effect on the Company and its Subsidiaries, taken as a whole.

   
  

     

   
  (z)            To the Company’s knowledge, there are no facts currently existing that will require the Company or any of its Subsidiaries to incur costs or liabilities associated with
      Environmental Laws (including, without limitation, any capital or operating expenditures required for clean-up, closure of properties or compliance with Environmental Laws or any permit, license or approval, any related constraints on operating
      activities and any potential liabilities to third parties) which would, singly or in the aggregate, have a material adverse effect on the Company and its Subsidiaries, taken as a whole.

   
  

     

   
  (aa)            The Company and its Subsidiaries possess all material certificates, authorizations and permits issued by the appropriate federal, state or foreign regulatory authorities necessary
      to conduct their respective business in the manner described in the Prospectus including, without limitation, (i) all U.S. Food and Drug Administration (the “FDA”)



      clearances and approvals necessary to conduct the Company’s business as now conducted and (ii) applicable foreign regulatory agency clearances, permits or approvals necessary to conduct the Company’s business as now conducted. Neither the Company nor
      any of its Subsidiaries has received any notice of proceedings relating to the revocation or modification of any such certificate, authorization or permit, including, without limitation, any FDA Form 483, notice of adverse finding, warning letter,
      untitled letter or other correspondence or notice from the FDA, any other governmental or regulatory authority or any third party which, singly or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would reasonably be
      expected to have a material adverse effect on the Company and its Subsidiaries, taken as a whole, except as described in the Prospectus.

   
  

     

   
  (bb)            The Company and each of its Subsidiaries have operated their businesses and currently are in compliance in all material respects with all applicable rules, regulations and
      policies of the FDA and any applicable comparable foreign regulatory organization, including, without limitation, all applicable directives and regulations of the European Medicines Agency. The Company has not received notice of any claim, action,
      suit, proceeding, hearing, enforcement, investigation, arbitration or other action from the FDA, any other federal, state, local or foreign governmental or regulatory authority or third party alleging that any product operation or activity is in
      material violation of any applicable laws or material certificates, authorizations or permits and has no knowledge that the FDA or any other federal, state, local or foreign governmental or regulatory authority or third party is considering any such
      claim, litigation, arbitration, action, suit, investigation or proceeding.

   
  

     

   
  
    
      


  

  (cc)            Except as disclosed in the Prospectus, none of the Company nor any of its Subsidiaries is or, since January 1, 2019 has
        been, in violation of any Health Care Laws, except where the failure to be in compliance would not, individually or in the aggregate, reasonably be expected to result in a material adverse effect on the Company and its Subsidiaries taken as a
        whole. For purposes of this Agreement, “Health Care Laws” means, to the extent applicable to the
        Company, (i) the Federal Food, Drug, and Cosmetic Act, and the regulations promulgated thereunder, (ii) all federal and state fraud and abuse laws, including, without limitation, the federal Anti-Kickback Statute (42 U.S.C. §1320a-7b(b)), the Stark
        Law (42 U.S.C. §1395nn), the civil False Claims Act (31 U.S.C. §3729 et seq.), Sections 1320a-7and 1320a-7a of Title 42 of the United States Code and the regulations promulgated pursuant to such statutes, (iii) the administrative simplification
        provisions of the Health Insurance Portability and Accountability Act of 1996 (18 U.S.C. §§669, 1035, 1347 and 1518; 42 U.S.C. §1320d et seq.) and the regulations promulgated thereunder, (iv) Titles XVIII (42 U.S.C. §1395 et seq.) and XIX (42
        U.S.C. §1396 et seq.) of the Social Security Act and the regulations promulgated thereunder, (v) the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (42 U.S.C. §1395w-101 et seq.) and the regulations promulgated thereunder,
        (vi) the so-called federal “Sunshine Law” or Open Payments (42 U.S.C. §1320a-7h) and state or local laws regulating or requiring reporting of interactions between pharmaceutical manufacturers and members of the healthcare industry and regulations
        promulgated thereunder, (vii) laws governing government pricing or price reporting programs and regulations promulgated thereunder, including without limitation the Medicaid Drug Rebate Program (42 U.S.C. § 1396r-8) and any state
      supplemental rebate program, the Public Health Service Act (42 U.S.C. § 256b), the VA Federal Supply Schedule (38 U.S.C. § 8126) or any state pharmaceutical assistance program or U.S. Department of Veterans Affairs agreement, and any successor
      government programs, (viii) all statutes, rules or regulations of applicable governmental authorities applicable to the ownership, testing, research, development, manufacture, quality, safety, accreditation, packaging, storage, use, distribution,
      labeling, promotion, sale, offer for sale, import, export or disposal of any product manufactured or distributed by the Company or its subsidiaries, including current good manufacturing practices requirements; and (ix) any and all other health care
      laws and regulations applicable to the Company or its Subsidiaries or their respective businesses, each as currently conducted, as described in the Prospectus, each of (i) through (ix) as may be amended from time to time.

   
  

     

   
  (dd)            Neither the Company nor any of its Subsidiaries has received written notice of any pending or threatened claim, suit, proceeding, hearing, enforcement, audit, investigation,
      arbitration or other legal action that has not been resolved from any applicable governmental authority or any third party, including employees, former employees or competitors, alleging that any operation or activity of the Company or any of its
      Subsidiaries is in violation of any applicable Health Care Laws, except as would not, singly or in the aggregate, reasonably be expected to result in a material adverse effect on the Company and its Subsidiaries taken as a whole. Except as would not,
      singly or in the aggregate, reasonably be expected to result in a material adverse effect on the Company and its Subsidiaries taken as a whole, (i) the Company and its Subsidiaries have timely submitted all registrations or other filings required
      under any applicable Health Care Laws with governmental authorities, (ii) and those filings have, to the knowledge of the Company, been complete and accurate when filed or corrected as appropriate by the Company if subsequently determined not to be
      complete or to be inaccurate.

   
  

     

   
  (ee)            Except as would not, singly or in the aggregate, reasonably be expected to result in a material adverse effect on the Company and its Subsidiaries taken as a whole, the Company
      (i) has in place current agreements for its marketed product to participate in Federal Health Care Programs; and (ii) is in compliance with all such agreements including, without limitation, provisions in such agreements pertaining to the timely and
      current submission of accurate prices to federal and state agencies. For purposes of this Agreement, “Federal Health Care Program” has the meaning set forth in 42 U.S.C. 1320a-7b(f).

   
  

     

   
  (ff)            The Company and its Subsidiaries have an operational healthcare compliance program that (i) governs all employees and contractors, including sales representatives; (ii) is
      materially consistent with the current U.S. Federal Sentencing Guidelines standards for effective compliance programs and U.S. Department of Health and Human Services Office of Inspector General Voluntary Compliance Guidance for Pharmaceutical
      Manufacturers; (iii) complies with the Pharmaceutical Research and Manufacturers of America Code on Interactions with Healthcare Professionals; and (iv) addresses compliance with Health Care Laws. The Company and each of its Subsidiaries operates in
      material compliance with such healthcare compliance program.

   
  

     

   
  
    
      


  

  (gg)            Neither the Company nor any of its subsidiaries is a party to any corporate integrity agreements, monitoring agreements, consent decrees, settlement orders or similar agreements
      with or imposed by any governmental authority.

   
  

     

   
  (hh)            None of the Company, its Subsidiaries, or any of their respective officers, directors, or employees, or to the knowledge of the Company, any independent contractor, is excluded,
      suspended or debarred from participation in any Federal Health Care Program or human research study or clinical trial or, to the knowledge of the Company, is or has been the subject of a governmental inquiry, investigation, proceeding or other
      action, including a criminal conviction or imposition of a civil monetary penalty, that would reasonably be expected to result in debarment, suspension, or exclusion. The Company periodically conducts screening of officers, directors, employees and
      independent contractors to confirm such persons are not excluded, suspended or debarred from participation in any Federal Health Care Program or human research study or clinical trial.

   
  

     

   
  (ii)            Except as described in the Prospectus or the Registration Statement, the Company and each of its Subsidiaries maintain a system of internal accounting controls sufficient to
      provide reasonable assurance that (i) transactions are executed in accordance with management’s general or specific authorizations; (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and
      to maintain asset accountability; (iii) access to assets is permitted only in accordance with management’s general or specific authorization; and (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals
      and appropriate action is taken with respect to any differences. Except as described in the Prospectus, since the end of the Company’s most recent audited fiscal year, there has been (A) no material weakness in the Company’s internal control over
      financial reporting (whether or not remediated) and (B) no change in the Company’s internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial
      reporting.

   
  

     

   
  (jj)            Neither the Company nor any of its Subsidiaries or affiliates, nor any director or officer, nor to the knowledge of the Company, any employee, agent or representative of the
      Company or of any of its Subsidiaries or affiliates, has taken any action (i) in violation of the Foreign Corrupt Practices Act of 1977, as amended, or any applicable law or regulation implementing the OECD Convention on Combating Bribery of Foreign
      Public Officials in International Business Transactions, and the Bribery Act 2010 of the United Kingdom or any other applicable anti-bribery or anti-corruption law (collectively “Anti-Corruption Laws”), or (ii) in furtherance of an offer, payment, promise to pay, or authorization or approval of the payment or giving or receiving of money, property, gifts or anything else of value (including nonmonetary
      benefits such as employment opportunities, gifts, travel, or entertainment), directly or indirectly, to any “government official” (including any officer or employee of a government or government-owned or controlled entity or of a public international
      organization, or any person acting in an official capacity for or on behalf of any of the foregoing, or any political party or party official or candidate for political office) or any other person to improperly influence official action, to
      improperly gain or retain business, or secure an improper advantage for the benefit of the Company. The Company and its Subsidiaries have conducted their businesses in compliance in all material respects with the Anti-Corruption Laws, and the Company
      and its Subsidiaries will not knowingly, directly or indirectly, use the proceeds of the offering and sale of the Shares, or lend, contribute or otherwise make available such proceeds to any subsidiary, affiliate, agent, partner or other person or
      entity, for the purpose of financing or facilitating any activity that would violate any of the Anti-Corruption Laws.

   
  

     

   
  
    
      


  

  (kk)            The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with applicable financial recordkeeping and reporting requirements,
      including, without limitation, those of the Bank Secrecy Act, as amended by Title III of the Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act of 2001, and the applicable anti-money
      laundering statutes of jurisdictions where the Company and its Subsidiaries conduct business, the rules and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by any governmental
      agency where the Company and its Subsidiaries conduct business (collectively, the “Anti-Money Laundering Laws”), and no action, suit or proceeding by or before any
      court or governmental agency, authority or body or any arbitrator involving the Company or any of its Subsidiaries with respect to the Anti-Money Laundering Laws is pending or, to the best knowledge of the Company, threatened.

   
  

     

   
  (ll)            Neither the Company nor any of its Subsidiaries or, any director, officer, or to the knowledge of the Company, any employee, agent, affiliate or representative of the Company or
      any of its Subsidiaries, is an individual or entity (“Person”) that is, or is owned or controlled by a Person that is: (i) the subject of any sanctions administered
      or enforced by the U.S. Department of Treasury’s Office of Foreign Assets Control (and including, without limitation, the designation as a “specially designated national” or “blocked person”), the United Nations Security Council, the European Union,
      Her Majesty’s Treasury or other relevant sanctions authority (collectively, “Sanctions”), nor (ii) located, organized or resident in a country or territory that is
      the subject of Sanctions (including, without limitation, Cuba, Iran, North Korea, Syria and the Crimea region of Ukraine). For the past five years, the Company has not knowingly engaged in and is not now knowingly engaged in any dealings or
      transactions with any Person, or in any country or territory, that at the time of the dealing or transaction is or was the subject of Sanctions.

   
  

     

   
  (mm)            The description of the results of the studies, tests and trials conducted by or on behalf of the Company contained in the Prospectus are accurate in all material respects and the
      Company has no knowledge of any other studies, tests or trials, the results of which are materially inconsistent with the results described in the Prospectus.

   
  

     

   
  (nn)            Any clinical trials or human and animal studies conducted by or on behalf of the Company and described in the Prospectus were and, if still pending, are being conducted (to the
      Company’s knowledge, after due inquiry, with respect to such studies conducted by third parties) in accordance, in all material respects, with standard medical and scientific research procedures, the Federal Food, Drug, and Cosmetic Act and the rules
      and regulations promulgated thereunder, and all applicable rules, regulations and policies of the FDA, including, where applicable, current good clinical practices and Good Laboratory Practices, as such terms are understood in the Company’s industry,
      and all applicable foreign regulatory requirements and standards. Except as described in the Prospectus or the Registration Statement, the Company has not received any notices or correspondence from the FDA or any other governmental authority
      contemplating or requiring the termination, suspension or modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of the Company, other than ordinary course communications with respect to modifications in
      connection with the design and implementation of such studies, trials and tests, none of which modifications would have a material impact on such study, trial or test.

   
  

     

   
  (oo)            The Company acknowledges and agrees that the Agent has informed the Company that the Agent may, to the extent permitted under the Securities Act and the Exchange Act, purchase and
      sell shares of Common Stock for its own account while this Agreement is in effect; provided, that (i) no such purchase or sales shall take place while a Placement
      Notice is in effect (except to the extent the Agent may engage in sales of Placement Shares purchased or deemed purchased from the Company as a “riskless principal” or in a similar capacity) and (ii) the Company shall not be deemed to have authorized
      or consented to any such purchases or sales by the Agent, except as may be otherwise agreed by the Company and the Agent.

   
  

     

   
  
    
      


  

  (pp)            The Company is not a party to any agreement with an agent or underwriter for any other “at the market” or continuous equity transaction.

   
  

     

   
  (qq)            Neither the Company nor any of its Subsidiaries, nor to the knowledge of the Company, any of its or their respective directors, officers or controlling persons, has taken,
      directly or indirectly, without giving effect to any actions taken by the Agent, (i) any action designed to result in or that constitutes, under the Exchange Act or otherwise, stabilization or manipulation of the price of any security of the Company
      to facilitate the sale or resale of the Placement Shares or (ii) any action in connection with the sale or resale of the Placement Shares that would reasonably be expected to cause or result in a violation of Regulation M under the Exchange Act.

   
  

     

   
  (rr)             Except as described in the Prospectus or the
    Registration Statement, the Company has not sold, issued or distributed any shares of Common Stock during the six-month period preceding the date hereof, including any sales pursuant to Rule 144A under, or Regulation D or S of, the Securities Act,
    other than shares issued pursuant to business combination or similar acquisition agreements, employee benefit plans, qualified stock option plans or other compensation or incentive plans or pursuant to the exercise or vesting of, as applicable,
    outstanding options, restricted stock units, other stock-based awards or inducement grants made to new employee hires.

   
  

     

   
  (ss)            Except as disclosed in the Registration Statement, the Company and each of its Subsidiaries are presently in compliance in all material respects with all applicable privacy and
      data protection laws, judgments, orders, and other contractual or legal obligations binding on the Company or its Subsidiaries; statutes, rules and regulations of any court or arbitrator or other governmental or regulatory authority, in each case,
      relating to the privacy and security of the information technology systems and personal data used in connection with the operation of the Company’s and its Subsidiaries’ businesses as currently conducted. The Company and each of its Subsidiaries
      have, in accordance with industry standard practices for companies comparable in size to the Company, taken steps designed to protect the information technology systems and personal data of the Company used in connection with the operation of the
      Company’s and its Subsidiaries’ businesses. Except as disclosed in the Prospectus or the Registration Statement and to the knowledge of the Company, there has been no material security breach, compromise, misuse, misappropriation, or unauthorized
      use, access, disablement, or modification of or relating to any such information technology system or personal data, and the Company and its Subsidiaries have not been notified of, and have no knowledge of any event or condition that would reasonably
      be expected to result in, any material security breach, compromise, misuse, misappropriation, or unauthorized use, access, disablement, or modification of or relating to any such information technology system or personal data.

   
  

     

   
  Any certificate signed by any officer of the Company and delivered to the Agent or its counsel in connection with the
    offering of the Placement Shares shall be deemed a representation and warranty by the Company, as to matters covered thereby, to the Agent.

   
  

     

   
  
    
      


  

  7.            Covenants of the Company.  The Company covenants and agrees with the Agent that:

   
  

     

   
  (a)            Registration Statement Amendments.  After the date of this Agreement and during any period in which the
      Prospectus relating to any Placement Shares is required to be delivered by the Agent under the Securities Act (including in circumstances where such requirement may be satisfied pursuant to Rule 172 under the Securities Act or a similar rule): (i)
      the Company will notify the Agent promptly of the time when any subsequent amendment to the Registration Statement, other than (A) Incorporated Documents and (B) any prospectus supplement filed in connection with an underwritten offering of
      securities of the Company, has been filed with the Commission and/or has become effective or any subsequent supplement to the Prospectus, other than Incorporated Documents, has been filed and of any request by the Commission for any amendment or
      supplement to the Registration Statement or Prospectus or for additional information; (ii) the Company will prepare and file with the Commission, promptly upon the Agent’s request, any amendments or supplements to the Registration Statement or
      Prospectus that, in the Agent’s reasonable opinion, may be necessary or advisable in connection with the distribution of the Placement Shares by the Agent (provided, however, that the failure of the Agent to make such request shall not relieve the
      Company of any obligation or liability hereunder, or affect the Agent’s right to rely on the representations and warranties made by the Company in this Agreement and provided, further, that the only remedy the Agent shall have with respect to the
      failure by the Company to make such filing (but without limiting the Agent’s rights under Section 9 hereof) will be to cease making sales under this Agreement until such amendment or supplement is filed); (iii) the Company will not file any amendment
      or supplement to the Registration Statement or Prospectus, other than Incorporated Documents, relating to the Placement Shares or a security convertible into or exchangeable or exercisable for the Placement Shares unless a copy thereof has been
      submitted to the Agent within a period of time sufficient to provide the Agent a reasonable opportunity to comment on any such proposed amendment or supplement before the filing and the
      Agent has not reasonably objected thereto (provided, however, that the failure of the Agent to make such objection shall not relieve the Company of any obligation or liability hereunder, or affect the Agent’s right to rely on the representations and
      warranties made by the Company in this Agreement and provided, further, that the only remedy the Agent shall have with respect to the Company’s making such filing notwithstanding the Agent’s objection (but without limiting the Agent’s rights under
      Section 9 hereof) will be to cease making sales under this Agreement),  and the Company will furnish to the Agent at the time of filing thereof a copy of any Incorporated Document, except for those documents available via EDGAR; and (iv) the Company
      will cause each amendment or supplement to the Prospectus, other than Incorporated Documents, to be filed with the Commission as required pursuant to the applicable paragraph of Rule 424(b) of the Securities Act within the time period prescribed.

   
  

     

   
  (b)            Notice of Commission Stop Orders.  The Company will advise the Agent, promptly after it receives notice or
      obtains knowledge thereof, of the issuance or threatened issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement, of the suspension of the qualification of the Placement Shares for offering or sale in
      any jurisdiction or of the initiation or threatening of any proceeding for any such purpose; and it will promptly use its commercially reasonable efforts to prevent the issuance of any stop order or to obtain its withdrawal if such a stop order
      should be issued.  The Company will advise the Agent promptly after it receives any request by the Commission for any amendments to the Registration Statement or any amendment or supplements to the Prospectus or for additional information related to
      the offering of the Placement Shares or for additional information related to the Registration Statement or the Prospectus.

   
  

     

   
  
    
      


  

  (c)            Delivery of Prospectus; Subsequent Changes.  During any period in which the Prospectus relating to the
      Placement Shares is required to be delivered by the Agent under the Securities Act with respect to the offer and sale of the Placement Shares (including in circumstances where such requirement may be satisfied pursuant to Rule 172 under the
      Securities Act or a similar rule), the Company will comply with all requirements imposed upon it by the Securities Act, as from time to time in force, and will file on or before their respective due dates (taking into account any extensions available
      under the Exchange Act) all reports and any definitive proxy or information statements required to be filed by the Company with the Commission pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act.  If during such period any event occurs
      as a result of which the Prospectus as then amended or supplemented would include an untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances then existing, not
      misleading, or if during such period it is necessary to amend or supplement the Registration Statement or Prospectus to comply with the Securities Act, the Company will promptly notify the Agent to suspend the offering of Placement Shares during such
      period and the Company will promptly amend or supplement the Registration Statement or Prospectus (at the expense of the Company) so as to correct such statement or omission or effect such compliance.  If the Company has omitted any information from
      the Registration Statement pursuant to Rule 430B under the Securities Act, it will use its best efforts to comply with the provisions thereof and make all requisite filings with the Commission pursuant to said Rule 430B and to notify the Agent
      promptly of all such filings if not available on EDGAR.

   
  

     

   
  (d)            Listing of Placement Shares.  During any period in which the Prospectus relating to the Placement Shares is
      required to be delivered by the Agent under the Securities Act with respect to the offer and sale of the Placement Shares (including in circumstances where such requirement may be satisfied pursuant to Rule 172 under the Securities Act or a similar
      rule), the Company will use its commercially reasonable efforts to (i) cause the Placement Shares to be listed on Nasdaq and (ii) timely file with Nasdaq all material documents and notices required by Nasdaq of companies that have or will issue
      securities that are traded on Nasdaq.

   
  

     

   
  (e)            Delivery of Registration Statement and Prospectus.  The Company will furnish to the Agent and its counsel
      (at the expense of the Company) copies of the Registration Statement (including exhibits thereto), the Prospectus (including all Incorporated Documents) and all amendments and supplements to the Registration Statement or Prospectus that are filed
      with the Commission during any period in which the Prospectus relating to the Placement Shares is required to be delivered under the Securities Act (including all Incorporated Documents filed with the Commission during such period), in each case as
      soon as reasonably practicable and in such quantities as the Agent may from time to time reasonably request and, at the Agent’s request, will also furnish copies of the Prospectus to each exchange or market on which sales of the Placement Shares may
      be made; provided, however, that the Company shall not be required to furnish any document (other than the Prospectus but excluding Incorporated Documents) to the Agent to the extent such document is available on EDGAR.

   
  

     

   
  (f)            Earnings Statement.  The Company will make generally available to its security holders and to the Agent as
      soon as practicable an earnings statement covering a 12-month period that satisfies the provisions of Section 11(a) of and Rule 158 under the Securities Act.

   
  

     

   
  (g)            Expenses.  The Company, whether or not the transactions contemplated hereunder are consummated or this
      Agreement is terminated in accordance with the provisions of Section 11 hereunder, will pay or cause to be paid all expenses incident to the performance of the Company’s obligations hereunder, including expenses relating to (i) the preparation,
      printing and filing of the Registration Statement and each amendment and supplement thereto, of the Prospectus and of each amendment and supplement thereto and of this Agreement, (ii) all costs and expenses related to the transfer and delivery of the
      Placement Shares and any taxes payable in connection therewith, (iii) the qualification of the Placement Shares under securities laws in accordance with the provisions of Section 7(s) of this Agreement, including filing fees and the reasonable fees
      and disbursements of counsel for the Agent in connection with such qualification and in connection with the Blue Sky or Legal Investment memorandum, (iv) the fees and expenses incurred in connection with the listing of the Placement Shares on Nasdaq,
      (v) the filing fees and expenses, if any, owed to the Commission or FINRA and the reasonable fees and disbursements of counsel to the Agent incurred in connection with the review and
      qualification, if any, of the offering of the Placement Shares by FINRA, (vi) the fees and expenses of any transfer agent or registrar for the Placement Shares and (vii) the reasonable fees and disbursements of the Agent’s outside legal counsel (A)
      in an amount not to exceed $50,000 arising out of executing this Agreement and the Company’s delivery of the initial certificate pursuant to Section 7(l) and (B) in an amount not to exceed $10,000 in connection with each Representation Date (as
      defined below) on which the Company is required to provide a certificate pursuant to Section 7(l) (in addition to the fees and associated expenses referred to in clause (v) above).

   
  

     

   
  
    
      


  

  (h)            Use of Proceeds.  The Company will use the Net Proceeds as described in the Prospectus in the section
      entitled “Use of Proceeds.”

   
  

     

   
  (i)            Notice of Other Sales.  The Company will not, directly or indirectly, (i) offer to sell, sell, contract to
      sell, grant any option to sell or otherwise dispose of any shares of Common Stock (other than the Placement Shares offered pursuant to this Agreement) or securities convertible into or exchangeable or exercisable for shares of Common Stock, warrants
      or any rights to purchase or acquire shares of Common Stock during the period beginning on the fifth Trading Day immediately prior to the date on which any Placement Notice is delivered to Agent hereunder and ending on the second Trading Day
      immediately following the final Settlement Date with respect to Placement Shares sold pursuant to such Placement Notice (or, if the Placement Notice has been terminated or suspended prior to the sale of all Placement Shares covered by a Placement
      Notice, the date of such suspension or termination), and (ii) will not directly or indirectly in any other “at the market offering” or continuous equity transaction offer to sell, sell, contract to sell, grant any option to sell or otherwise dispose
      of any shares of Common Stock (other than the Placement Shares offered pursuant to this Agreement) or securities convertible into or exchangeable or exercisable for shares of Common Stock, prior to the termination of this Agreement, in each case, (i)
      and (ii), unless the Company provides prior written notice to the Agent; provided, however,
      that such notice will not be required in connection with (A) the issuance by the Company of Common Stock upon the exercise of outstanding stock options or other stock-based awards or vesting of outstanding restricted stock units or other stock-based
      awards or issuances of shares of Common Stock under the 2000 Plan, the 2013 Plan, the 2015 Plan, the 2017 Plan or the 2019 Plan or pursuant to inducement grants to new employees or upon the exercise of currently outstanding options granted outside of
      such plans, (B) the grant by the Company of stock options, restricted stock units or other stock-based awards under the 2019 Plan or pursuant to inducement grants to new employees, (C) the conversion of a security outstanding on the date hereof
      described in the Registration Statement or of which the Agent has been advised in writing or (D) issuances of Common Stock or other securities in connection with a transaction that includes a commercial relationship (including joint ventures,
      marketing or distribution arrangements, collaboration agreements or intellectual property license agreements) or any business combination transaction or other acquisition of assets or equity of another entity provided that the aggregate number of
      shares of securities issued pursuant to this clause (D) shall not exceed 10% of the total number of outstanding shares of Common Stock immediately prior to such transaction.

   
  

     

   
  (j)            Due Diligence Cooperation and Change of Circumstances.

   
  

     

   
  (i)             During the term of this Agreement, the
    Company will cooperate with any reasonable due diligence review conducted by the Agent, its affiliates agents and counsel from time to time in connection with the transactions contemplated hereby, including providing information and making available
    documents and senior corporate officers, during regular business hours and at the Company’s principal offices, as the Agent may reasonably request.

   
  

     

   
  (ii)             The Company will, at any time during a
    fiscal quarter in which the Company intends to tender a Placement Notice or sell Placement Shares, advise the Agent promptly after it shall have received notice or obtained knowledge of any information or fact that would alter or affect in any material
    respect any opinion, certificate, letter or other document provided or required to be provided to the Agent pursuant to this Agreement during such fiscal quarter.

   
  

     

   
  
    
      


  

  (k)            Required Filings Relating to Placement of Placement Shares.  The Company agrees that on or prior to such
      dates as the Securities Act shall require, the Company will (i) file a prospectus supplement with the Commission under the applicable paragraph of Rule 424(b) under the Securities Act, which prospectus supplement will set forth, within the relevant
      period, the number or amount of Placement Shares sold through the Agent, the Net Proceeds to the Company and the compensation payable by the Company to the Agent with respect to such Placement Shares, and (ii) deliver such number of copies of each
      such prospectus supplement to each exchange or market on which such sales were effected as may be required by the rules or regulations of such exchange or market; provided,
      that, unless a prospectus supplement containing such information is required to be filed under the Securities Act, the requirement of this Section 7(k) may be satisfied by Company’s inclusion in the Company’s Form 10-K or Form 10-Q, as applicable, of
      the number or amount of Placement Shares sold through the Agent, the Net Proceeds to the Company and the compensation payable by the Company to the Agent with respect to such Placement Shares during the relevant period.

   
  

     

   
  (l)            Representation Dates; Certificate.  On or prior to the date on which the Company first delivers a Placement
      Notice pursuant to this agreement (the “First Placement Notice Date”) and each time the Company:

   
  

     

   
  (i)            amends or supplements the Registration Statement or the Prospectus relating to the Placement Shares (other than a prospectus supplement filed in accordance with Section 7(k) of
      this Agreement) by means of a post-effective amendment, sticker or supplement but not by means of incorporation of document(s) by reference into the Registration Statement or the Prospectus relating to the Placement Shares;

   
  

     

   
  (ii)            files an annual report on Form 10-K under the Exchange Act (including any Form 10-K/A containing amended financial information or a material amendment to the previously filed Form
      10-K);

   
  

     

   
  (iii)            files a quarterly report on Form 10-Q under the Exchange Act; or

   
  

     

   
  (iv)            files a current report on Form 8-K containing financial information of the Company that amends financial information included in a previously filed Form 10-K or Form 10-Q of the
      Company (other than an earnings release that is “furnished” pursuant to Item 2.02 or Item 7.01 of Form 8-K) under the Exchange Act (each date of filing of one or more of the documents referred to in clauses (i) through (iv) shall be a “Representation Date”),

   
  

     

   
  the Company shall furnish the Agent (but in the case of clause (iv) above only if (1) a Placement Notice is pending or in effect and (2)
    the Agent requests such certificate within three Business Days after the filing of such Form 8-K with the Commission) with a certificate, in the form attached hereto as Exhibit


        7(l) (modified, as necessary, to relate to the Registration Statement and the Prospectus as then amended or supplemented), within two Trading Days of any
    Representation Date.  The requirement to provide a certificate under this Section 7(l) shall be waived for any Representation Date occurring at a time at which no Placement Notice is pending or in effect, which waiver shall continue until the earlier
    to occur of (1) the date the Company delivers a Placement Notice hereunder (which for such calendar quarter shall be considered a Representation Date) and (2) the next occurring Representation Date.  Notwithstanding the foregoing, if the Company
    subsequently decides to sell Placement Shares following a Representation Date on which the Company relied on the waiver referred to in the previous sentence and did not provide the Agent with a certificate under this Section 7(l), then before the
    Company delivers a Placement Notice or the Agent sells any Placement Shares pursuant thereto, the Company shall provide the Agent with a certificate, in the form attached hereto as Exhibit 7(l), dated the date of such Placement Notice.

   
  

     

   
  
    
      


  

  (m)            Legal Opinions.  On or prior to the First Placement Notice Date and on any date which the Company is
      obligated to deliver a certificate pursuant to Section 7(l) for which no waiver is applicable, the Company shall cause to be furnished to the Agent (i) the written opinion and negative assurance letter of Covington & Burlington LLP, special
      counsel to the Company, or such other counsel satisfactory to the Agent (“Company Counsel”), in substantially the form previously agreed, dated the date that
      the opinion and negative assurance letter are required to be delivered, modified, as necessary, to relate to the Registration Statement and the Prospectus as then amended or supplemented; provided, however, that in lieu of such opinion and negative assurance letter for subsequent Representation Dates, Company Counsel may
      furnish the Agent with a letter to the effect that the Agent may rely on a prior opinion or negative assurance letter delivered by such counsel under this Section 7(m) to the same extent as if it were dated the date of such letter (except that
      statements in such prior opinion or negative assurance letter shall be deemed to relate to the Registration Statement and the Prospectus as amended or supplemented at such Representation Date and (ii) the written opinion of Hunton Andrews Kurth LLP,
      Virginia counsel to the Company, or such other counsel satisfactory to the Agent (“Virginia Counsel”), in substantially the form previously agreed, dated the
      date that the opinion is required to be delivered, modified, as necessary, to relate to the Registration Statement and the Prospectus as then amended or supplemented; provided,
      however, that in lieu of such opinion for subsequent Representation Dates, Virginia Counsel may furnish the Agent with a letter to the effect that the Agent may rely
      on a prior opinion delivered by such counsel under this Section 7(m) to the same extent as if it were dated the date of such letter (except that statements in such prior opinion shall be deemed to relate to the Registration Statement and the
      Prospectus as amended or supplemented at such Representation Date).

   
  

     

   
  (n)            Intellectual Property Opinion. On or prior to the First Placement Notice Date and on any date which the
      Company is obligated to deliver a certificate pursuant to Section 7(l) for which no waiver is applicable, the Company shall cause to be furnished to the Agent the written opinion of Cooley LLP, counsel for the Company with respect to intellectual
      property matters, or such other intellectual property counsel satisfactory to the Agent (“Intellectual Property Counsel”), in substantially the form previously
      agreed, dated the date that the opinion letter is required to be delivered, modified, as necessary, to relate to the Registration Statement and the Prospectus as then amended or supplemented; provided, however, that in lieu of such written opinion for subsequent Representation Dates, Intellectual Property Counsel may furnish
      the Agent with a letter to the effect that the Agent may rely on a prior opinion letter delivered by such counsel under this Section 7(n) to the same extent as if it were dated the date of such opinion letter (except that statements in such prior
      opinion letter shall be deemed to relate to the Registration Statement and the Prospectus as amended or supplemented at such Representation Date).

   
  

     

   
  (o)            Comfort Letter.  On or prior to the First Placement Notice Date and on any date which the Company is
      obligated to deliver a certificate pursuant to Section 7(l) for which no waiver is applicable, the Company shall cause its independent registered public accounting firm (and any other independent accountants whose report is included in the
      Registration Statement or the Prospectus) to furnish the Agent letters (the “Comfort Letters”), dated the date the Comfort Letter is delivered, which shall
      meet the requirements set forth in this Section 7(o); provided, that if requested by the Agent, the Company shall cause a Comfort Letter to be furnished to the
      Agent within 10 Trading Days of the occurrence of any material transaction or event that necessitates the filing of additional, pro forma, amended or revised financial statements (including any restatement of previously issued financial statements). 
      Each Comfort Letter shall be in form and substance satisfactory to the Agent and each Comfort Letter from the Company’s independent registered public accounting firm and shall (i) contain statements and information of the type ordinarily included in
      accountants’ “comfort letters” to sales agents with respect to the financial statements and certain financial information contained in the Registration Statement and the Prospectus (the first such letter, the “Initial Comfort Letter”) and (ii) update the Initial Comfort Letter with any information that would have been included in the Initial Comfort Letter had it been given on such date and modified
      as necessary to relate to the Registration Statement and the Prospectus, as amended and supplemented to the date of such letter.

   
  

     

   
  
    
      


  

  (p)            Investment Company Act.  The Company will conduct its affairs in such a manner so as to reasonably ensure
      that it will not be or become, at any time prior to the termination of this Agreement, required to be registered as an “investment company,” as such term is defined in the Investment Company Act.

   
  

     

   
  (q)            Market Activities.  The Company will not, directly or indirectly, and will cause its officers, directors
      and Subsidiaries not to sell, bid for, or purchase share of Common Stock in violation of Regulation M, or pay anyone any compensation for soliciting purchases of the Placement Shares other than the Agent; provided, however, that the Company may bid for and purchase shares of Common Stock in accordance with Rule 10b-18
      under the Exchange Act.

   
  

     

   
  (r)            No Offer to Sell.  Other than the Registration Statement, the Prospectus or a free writing prospectus (as
      defined in Rule 405 under the Securities Act) approved in advance by the Company and the Agent, neither the Agent nor the Company (including its agents and representatives, other than the Agent in its capacity as agent) will make, use, prepare,
      authorize, approve or refer to any written communication (as defined in Rule 405 under the Securities Act), required to be filed with the Commission, that constitutes an offer to sell or solicitation of an offer to buy Placement Shares hereunder.

   
  

     

   
  (s)            Blue Sky and Other Qualifications. The Company will use its commercially reasonable efforts, in cooperation
      with the Agent, to qualify the Placement Shares for offering and sale, or to obtain an exemption for the Placement Shares to be offered and sold, under the applicable securities laws of such states and other jurisdictions (domestic or foreign) as the
      Agent may designate and to maintain such qualifications and exemptions in effect for so long as required for the distribution of the Placement Shares (but in no event for less than one year from the date of this Agreement); provided, however, that the Company shall not be obligated to file any general consent to service of process or to qualify as a foreign corporation or as a dealer in securities in any
      jurisdiction in which it is not so qualified or to subject itself to taxation in respect of doing business in any jurisdiction in which it is not otherwise so subject. In each jurisdiction in which the Placement Shares have been so qualified or
      exempt, the Company will file such statements and reports as may be required by the laws of such jurisdiction to continue such qualification or exemption, as the case may be, in effect for so long as required for the distribution of the Placement
      Shares (but in no event for less than one year from the date of this Agreement).

   
  

     

   
  (t)            Renewal of Registration Statement. If, immediately prior to the third anniversary of the initial effective
      date of the Registration Statement (the “Renewal Date”), any of the Placement Shares remain unsold and this Agreement has not been terminated, the Company
      will, prior to the Renewal Date, file a new shelf registration statement or, if applicable, an automatic shelf registration statement relating to the Common Stock that may be offered and sold pursuant to this Agreement (which shall include a
      prospectus reflecting the number or amount of Placement Shares that may be offered and sold pursuant to this Agreement), in a form satisfactory to the Agent and its counsel, and, if such registration statement is not an automatic shelf registration
      statement, will use its best efforts to cause such registration statement to be declared effective within 180 days after the Renewal Date. The Company will take all other reasonable actions necessary or appropriate to permit the public offer and sale
      of the Placement Shares to continue as contemplated in the expired registration statement and this Agreement. From and after the effective date thereof, references herein to the “Registration Statement” shall include such new shelf registration
      statement or such new automatic shelf registration statement, as the case may be.

   
  

     

   
  (u)            General Instruction I.B.6. of Form S-3. If, from and after the date of this Agreement, the Company is no
      longer eligible to use Form S-3 (including pursuant to General Instruction I.B.6.) at the time it files with the Commission an annual report on Form 10-K or any post-effective amendment to the Registration Statement, then it shall promptly notify the
      Agent and, within two Business Days after the date of filing of such annual report on Form 10-K or amendment to the Registration Statement, the Company shall file a new prospectus supplement with the Commission reflecting the number of shares of
      Common Stock available to be offered and sold by the Company under this Agreement pursuant to General Instruction I.B.6. of Form S-3; provided, however, that the Company may delay the filing of any such prospectus supplement for up to 30 days if, in the reasonable judgment of the Company, it is in the best
      interest of the Company to do so, provided that no Placement Notice is in effect or pending during such time. Until such time as the Company shall have corrected such misstatement or omission or effected such compliance, the Company shall not notify
      the Agent to resume the offering of Placement Shares.

   
  

     

   
  
    
      


  

  (v)            Tax Indemnity. The Company will indemnify and hold harmless the Agent against any documentary, stamp or
      similar issue tax, including any interest and penalties, on the issue and sale of the Placement Shares.

   
  

     

   
  (w)            Transfer Agent. The Company has engaged and will maintain, at its sole expense, a transfer agent and
      registrar for the Common Stock.

   
  

     

   
  8.            Conditions to the Agent’s Obligations. The obligations of the Agent hereunder with respect to a Placement
      will be subject to the continuing accuracy and completeness of the representations and warranties made by the Company herein, to the due performance by the Company of its obligations hereunder, to the completion by the Agent of a due diligence review
      satisfactory to the Agent in its reasonable judgment, and to the continuing satisfaction (or waiver by the Agent in its sole discretion) of the following additional conditions:

   
  

     

   
  (a)            Registration Statement Effective.  The Registration Statement shall be effective and shall be available for
      all offers and sales of Placement Shares (i) that have been issued pursuant to all prior Placement Notices and (ii) that will be issued pursuant to any Placement Notice.

   
  

     

   
  (b)            Prospectus Supplement. The Company shall have filed with the Commission the Prospectus Supplement pursuant
      to Rule 424(b) under the Securities Act not later than the Commission’s close of business on the second Business Day following the date of this Agreement.

   
  

     

   
  (c)            No Material Notices.  None of the following events shall have occurred and be continuing: (i) receipt by
      the Company or any of its Subsidiaries of any request for additional information from the Commission or any other federal or state governmental authority during the period of effectiveness of the Registration Statement, the response to which would
      require any post-effective amendments or supplements to the Registration Statement or the Prospectus; (ii) the issuance by the Commission or any other federal or state governmental authority of any stop order suspending the effectiveness of the
      Registration Statement or the initiation of any proceedings for that purpose; (iii) receipt by the Company or any of its Subsidiaries of any notification with respect to the suspension of the qualification or exemption from qualification of any of
      the Placement Shares for sale in any jurisdiction or the initiation or threatening of any proceeding for such purpose; or (iv) the occurrence of any event that makes any material statement made in the Registration Statement or the Prospectus untrue
      in any material respect or that requires the making of any changes in the Registration Statement or the Prospectus so that, in the case of the Registration Statement, it will not contain any untrue statement of a material fact or omit to state any
      material fact required to be stated therein or necessary to make the statements therein not misleading and, in the case of the Prospectus, so that it will not contain any untrue statement of a material fact or omit to state any material fact required
      to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading.

   
  

     

   
  
    
      


  

  (d)            No Misstatement or Material Omission. The Agent shall not have advised the Company that the Registration
      Statement or Prospectus, or any amendment or supplement thereto, contains an untrue statement of fact that in the Agent’s opinion is material, or omits to state a fact that in the Agent’s opinion is material and is required to be stated therein or is
      necessary to make the statements therein not misleading.

   
  

     

   
  (e)            Material Changes.  Except as contemplated in the Prospectus, or disclosed in the Company’s reports filed
      with the Commission, there shall not have been any material adverse change, on a consolidated basis, in the authorized capital stock of the Company, or any downgrading in or withdrawal of the rating assigned to any of the Company’s securities (other
      than asset backed securities), if any, by any rating organization or a public announcement by any rating organization that it has under surveillance or review its rating of any of the Company’s securities (other than asset backed securities), if any,
      the effect of which, in the judgment of the Agent (without relieving the Company of any obligation or liability it may otherwise have), is so material as to make it impracticable or inadvisable to proceed with the offering of the Placement Shares on
      the terms and in the manner contemplated in the Prospectus.

   
  

     

   
  (f)            Company Counsel Legal Opinions.  The Agent shall have received the opinions and negative assurance letters,
      as applicable, of Company Counsel and Intellectual Property Counsel required to be delivered pursuant to Section 7(m) and Section 7(n), as applicable, on or before the date on which such delivery of such opinions and negative assurance letters are
      required pursuant to Section 7(m) and Section 7(n), as applicable.

   
  

     

   
  (g)            Agent’s Counsel Legal Opinion.  The Agent shall have received from Ropes & Gray LLP, counsel for the
      Agent, such opinion or opinions, on or before the date on which the delivery of the Company Counsel legal opinion is required pursuant to Section 7(m), with respect to such matters as the Agent may reasonably require, and the Company shall have
      furnished to such counsel such documents as they may request to enable them to pass upon such matters.

   
  

     

   
  (h)            Comfort Letter.  The Agent shall have received the Comfort Letter required to be delivered pursuant to
      Section 7(o) on or before the date on which such delivery of such Comfort Letter is required pursuant to Section 7(o).

   
  

     

   
  (i)            Representation Certificate.  The Agent shall have received the certificate required to be delivered
      pursuant to Section 7(l) on or before the date on which delivery of such certificate is required pursuant to Section 7(l).

   
  

     

   
  (j)            Secretary’s Certificate. On or prior to the First Placement Notice Date, the Agent shall have received a
      certificate, signed on behalf of the Company by the Secretary of the Company and attested to by an executive officer of the Company, dated as of such date and in form and substance previously agreed, certifying as to (i) the amended and restated
      certificate of incorporation of the Company, (ii) the amended and restated bylaws of the Company, (iii) the resolutions of the board of directors of the Company or duly authorized committee thereof authorizing the execution, delivery and performance
      of this Agreement and the issuance and sale of the Placement Shares and (iv) the incumbency of the officers of the Company duly authorized to execute this Agreement and the other documents contemplated by this Agreement (including each of the
      officers set forth on Schedule 2).

   
  

     

   
  (k)            No Suspension.  The Common Stock shall be duly listed, and admitted and authorized for trading, subject to
      official notice of issuance, on Nasdaq. Trading in the Common Stock shall not have been suspended on, and the Common Stock shall not have been delisted from, Nasdaq.

   
  

     

   
  
    
      


  

  (l)            Securities Act Filings Made.  All filings with the Commission required by Rule 424(b) or Rule 433 under the
      Securities Act to have been filed prior to the issuance of any Placement Notice hereunder shall have been made within the applicable time period prescribed for such filing by Rule 424(b) (without reliance on Rule 424(b)(8) of the Securities Act) or
      Rule 433, as applicable.

   
  

     

   
  (m)            Approval for Listing.  Either (i) the Placement Shares shall have been approved for listing on Nasdaq,
      subject only to notice of issuance, or (ii) the Company shall have filed an application for listing of the Placement Shares on Nasdaq at, or prior to, the First Placement Notice Date and Nasdaq shall have reviewed such application and not provided
      any objections thereto.

   
  

     

   
  (n)            FINRA.  FINRA shall have raised no objection to the terms of the offering contemplated hereby and the
      amount of compensation allowable or payable to the Agent as described in the Prospectus.

   
  

     

   
  (o)            No Termination Event.  There shall not have occurred any event that would permit the Agent to terminate
      this Agreement pursuant to Section 11(a).

   
  

     

   
  9.            Indemnification and Contribution.

   
  

     

   
  (a)            Company Indemnification.  The Company agrees to indemnify and hold harmless the Agent and its directors,
      officers, employees, affiliates and agents, and each person, if any, who controls the Agent within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act and
      each affiliate of the Agent within the meaning of Rule 405 under the Securities Act from and against any and all losses, claims, damages and liabilities (including, without limitation, any legal or other expenses reasonably incurred in connection
      with defending or investigating any such action or claim) caused by (x) any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement or the Prospectus (or any amendment or supplement to the Registration
      Statement or the Prospectus) or in any free writing prospectus or (y) the omission or alleged omission to state in any such document a material fact required to be stated therein or necessary to make the statements therein (solely with respect to the
      Prospectus, in light of the circumstances under which they were made) not misleading; provided, however, that in each case, this indemnity agreement shall not apply to the extent that such losses, claims, damages or liabilities are caused by any such untrue statement or omission or alleged untrue statement or
      omission based upon the Agent’s Information.

   
  

     

   
  (b)            Agent Indemnification. The Agent agrees to indemnify and hold harmless the Company and its directors and
      each officer of the Company who signed the Registration Statement, and each person, if any, who controls the Company within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act to the same extent as the foregoing
      indemnity from the Company to the Agent, but only with reference to the Agent’s Information.

   
  

     

   
  
    
      


  

  (c)            Procedure.  In case any proceeding (including any governmental investigation) shall be instituted involving
      any person in respect of which indemnity may be sought pursuant to Section 8(a) or 8(b), such person (the “indemnified party”) shall promptly notify the person
      against whom such indemnity may be sought (the “indemnifying party”) in writing and the indemnifying party, upon request of the indemnified party, shall retain
      counsel reasonably satisfactory to the indemnified party to represent the indemnified party and any others the indemnifying party may designate in such proceeding and shall pay the reasonably incurred fees and disbursements of such counsel related to
      such proceeding. In any such proceeding, any indemnified party shall have the right to retain its own counsel, but the fees and expenses of such counsel shall be at the expense of such indemnified party unless (i) the indemnifying party and the
      indemnified party shall have mutually agreed to the retention of such counsel, (ii) the named parties to any such proceeding (including any impleaded parties) include both the indemnifying party and the indemnified party and representation of both
      parties by the same counsel would be inappropriate due to actual or potential differing interests between them or (iii) the use of counsel chosen by the indemnifying party to represent the indemnified party would present such counsel with a conflict
      of interest. It is understood that the indemnifying party shall not, in respect of the legal expenses of any indemnified party in connection with any proceeding or related proceedings in the same jurisdiction, be liable for the fees, disbursements
      and other charges of more than one separate firm (plus local counsel) for all such indemnified parties, and that all such fees and expenses shall be reimbursed as they are incurred. Such firm shall be designated in writing by the Agent, in the case
      of parties indemnified pursuant to Section 9(a), and by the Company, in the case of parties indemnified pursuant to Section 9(b). An indemnifying party will not, in any event, be liable for any settlement of any action or claim effected without its
      written consent, but if settled with such consent or if there be a final judgment for the plaintiff, the indemnifying party agrees to indemnify the indemnified party from and against any loss or liability by reason of such settlement or judgment.  No
      indemnifying party shall, without the prior written consent of each indemnified party, effect any settlement of any pending or threatened proceeding in respect of which an indemnified party is or could have been a party and indemnity could have been
      sought hereunder by such indemnified party, unless such settlement (1) includes an unconditional release of such indemnified party from all liability on claims that are the subject matter of such proceeding and (2) does not include a statement as to
      or an admission of fault, culpability or a failure to act by or on behalf of any indemnified party.

   
  

     

   
  (d)            Contribution.  To the extent the indemnification provided for in Section 9(a) or 9(b) is unavailable to an
      indemnified party or insufficient in respect of any losses, claims, damages or liabilities referred to therein, then each indemnifying party under such paragraph, in lieu of indemnifying such indemnified party thereunder, shall contribute to the
      amount paid or payable by such indemnified party as a result of such losses, claims, damages or liabilities (i) in such proportion as is appropriate to reflect the relative benefits received by the indemnifying party or parties on the one hand and
      the indemnified party or parties on the other hand from the offering of the Placement Shares or (ii) if the allocation provided by Section 9(d)(i) above is not permitted by applicable law, in such proportion as is appropriate to reflect not only the
      relative benefits referred to in Section 9(d)(i) above but also the relative fault of the indemnifying party or parties on the one hand and of the indemnified party or parties on the other hand in connection with the statements or omissions that
      resulted in such losses, claims, damages or liabilities, as well as any other relevant equitable considerations. The relative benefits received by the indemnifying party or parties on the one hand and the indemnified party or parties on the other
      hand in connection with the offering of the Placement Shares shall be deemed to be in the same proportion as the total Net Proceeds from the sale of the Placement Shares (before deducting expenses) received by the Company bear to the total
      compensation received by the Agent from the sale of Placement Shares on behalf of the Company.  The relative fault of the indemnifying party or parties on the one hand and the indemnified party or parties on the other hand shall be determined by
      reference to, among other things, whether the untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material fact relates to information supplied by the indemnifying party or parties on the one hand or the
      indemnified party or parties on the other hand, and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. The Company and the Agent agree that it would not be just and
      equitable if contributions pursuant to this Section 9(d) were to be determined by pro rata allocation or by any other method of allocation that does not take into
      account the equitable considerations referred to herein. The amount paid or payable by an indemnified party as a result of the losses, claims, damages and liabilities referred to above in this Section 9(d) shall be deemed to include, subject to the
      limitations set forth above, any legal or other expenses reasonably incurred by such indemnified party in connection with investigating or defending any such action or claim.  Notwithstanding the foregoing provisions of this Section 9(d), the Agent
      shall not be required to contribute any amount in excess of the commissions received by it under this Agreement and no person found guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) will be entitled to
      contribution from any person who was not guilty of such fraudulent misrepresentation.

   
  

     

   
  
    
      


  

  10.            Representations and Agreements to Survive Delivery.  The indemnity and contribution agreements contained in
      Section 9 of this Agreement and all representations and warranties of the Company herein shall survive, as of their respective dates, regardless of (i) any investigation made by or on behalf of the Agent, any person controlling the Agent or any
      affiliate of the Agent, or by or on behalf of the Company, its officers or directors or any person controlling the Company, (ii) delivery and acceptance of the Placement Shares and payment therefor or (iii) any termination of this Agreement.

   
  

     

   
  11.            Termination.

   
  

     

   
  (a)            The Agent shall have the right, by giving notice as hereinafter specified, at any time to terminate this Agreement if (i) any material adverse effect, or any development that
      could reasonably be expected to result in a material adverse effect on the Company and its Subsidiaries, taken as a whole, has occurred that, in the judgment of the Agent, will materially impair the ability of the Agent to sell the Placement Shares
      hereunder, (ii) any suspension or limitation of trading in the Common Stock or in securities generally on Nasdaq shall have occurred, (iii) a general banking moratorium shall have been declared by any of United States federal or New York authorities,
      or (iv) there shall have occurred any outbreak or escalation of national or international hostilities or any crisis or calamity, or any adverse change in the United States or international financial markets, or any substantial change or development
      involving a prospective substantial change in United States or international political, financial or economic conditions that, in the judgment of the Agent, may materially impair the ability of the Agent to sell the Placement Shares hereunder or to
      enforce contracts for the sale of securities. Any such termination shall be without liability of any party to any other party except that the provisions of Section 7(g), Section 9, Section 10, Section 16 and Section 17 hereof shall remain in full
      force and effect notwithstanding such termination. If the Agent elects to terminate this Agreement as provided in this Section 11(a), the Agent shall provide the required notice as specified in Section 12.

   
  

     

   
  (b)            The Company shall have the right, by giving 10 days’ prior notice as hereinafter specified, to terminate this Agreement in its sole discretion at any time after the date of this
      Agreement.  Any such termination shall be without liability of any party to any other party except that the provisions of Section 7(g), Section 9, Section 10, Section 11(f), Section 16 and Section 17 hereof shall remain in full force and effect
      notwithstanding such termination.

   
  

     

   
  (c)            The Agent shall have the right, by giving 10 days’ prior notice as hereinafter specified, to terminate this Agreement in its sole discretion at any time after the date of this
      Agreement.  Any such termination shall be without liability of any party to any other party except that the provisions of Section 7(g), Section 9, Section 10, Section 11(f), Section 16 and Section 17 hereof shall remain in full force and effect
      notwithstanding such termination.

   
  

     

   
  (d)            Unless earlier terminated pursuant to this Section 11, this Agreement shall automatically terminate upon the issuance and sale of all of the Placement Shares through the Agent on
      the terms and subject to the conditions set forth herein; provided that the provisions of Section 7(g), Section 9, Section 10, Section 11(f), Section 16 and Section
      17 hereof shall remain in full force and effect notwithstanding such termination.

   
  

     

   
  (e)            This Agreement shall remain in full force and effect unless terminated pursuant to Sections 11(a), (b), (c), or (d) above or otherwise by mutual agreement of the parties; provided, however, that any such termination by mutual agreement shall in all cases
      be deemed to provide that Section 7(g), Section 9, Section 10, Section 11(f), Section 16 and Section 17 shall remain in full force and effect.

   
  

     

   
  
    
      


  

  (f)            Any termination of this Agreement shall be effective on the date specified in such notice of termination; provided, however, that such termination shall not be effective until the close of business on the date of receipt of such notice by the Agent or the Company, as the case may be. If such termination shall occur prior to the
      Settlement Date for any sale of Placement Shares, such Placement Shares shall settle in accordance with the provisions of this Agreement. Upon termination of this Agreement, the Company shall not be required to pay to the Agent any discount or
      commission with respect to any Placement Shares not otherwise sold by the Agent under this Agreement; provided, however, that the Company shall remain obligated to reimburse the Agent’s expenses pursuant to Section 7(g).

   
  

     

   
  12.            Notices.  All notices or other communications required or permitted to be given by any party to any other
      party pursuant to the terms of this Agreement shall be in writing, unless otherwise specified in this Agreement, and if sent to the Agent, shall be delivered to:

   
  

     

   
  SVB Leerink LLC

   
  1301 Avenue of the Americas, 12th Floor

   
  New York, New York  10019

   
  Attention: Peter M. Fry

   
  E-mail: peter.fry@svbleerink.com

   
  

     

   
  with a copy (which shall not constitute notice) to:

   
  

     

   
  SVB Leerink LLC

   
  1301 Avenue of the Americas, 12th Floor

   
  New York, New York  10019

   
  Attention: Stuart R. Nayman, Esq.

   
  E-mail: stuart.nayman@svbleerink.com

   
  

     

   
  and if to the Company, shall be delivered to:

   
  

     

   
  Insmed Incorporated

   
  700 US Highway 202/206

   
  Bridgewater, New Jersey 08807

   
  Attention: Chief Legal Officer

     
  

     

   
  with copies (which shall not constitute notice) to:

   
  

     

   
  Covington & Burling LLP

   
  One City Center, 850 Tenth Street NW 

   
  Washington, DC 20001-4956

   
  Attention: Michael J. Riella

   
  E-mail: mriella@cov.com

   
  

     

   
  Each party to this Agreement may change such address for notices by sending to the parties to this Agreement written notice of a new
    address for such purpose.  Each such notice or other communication shall be deemed given (i) when delivered personally on or before 4:30 P.M., New York City time, on a Business Day, or, if such day is not a Business Day, on the next succeeding Business
    Day, (ii) by Electronic Notice as set forth in the next paragraph, (iii) on the next Business Day after timely delivery to a nationally-recognized overnight courier or (iv) on the Business Day actually received if deposited in the U.S. mail (certified
    or registered mail, return receipt requested, postage prepaid). For purposes of this Agreement, “Business Day” shall mean any day on which the Nasdaq and
    commercial banks in the City of New York are open for business.

   
  

     

   
  
    
      


  

  An electronic communication (“Electronic Notice”)



    shall be deemed written notice for purposes of this Section 12 if sent to the electronic mail address specified by the receiving party in Section 12. Electronic Notice shall be deemed received at the time the party sending Electronic Notice receives
    actual acknowledgment of receipt from the person whom the notice is sent, other than via auto-reply. Any party receiving Electronic Notice may request and shall be entitled to receive the notice on paper, in a nonelectronic form (“Nonelectronic Notice”), which shall be sent to the requesting party within 10 days of receipt of the written request for Nonelectronic Notice.

   
  

     

   
  13.            Successors and Assigns.  This Agreement shall inure to the benefit of and be binding upon the Company and
      the Agent and their respective successors and the affiliates, controlling persons, officers, directors and other persons referred to in Section 9 hereof. References to any of the parties contained in this Agreement shall be deemed to include the
      successors and permitted assigns of each such party. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto, the persons referred to in the preceding sentence and their respective successors
      and permitted assigns any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement. Neither party may assign its rights or obligations under this Agreement without the prior
      written consent of the other party.

   
  

     

   
  14.            Adjustments for Share Splits.  The parties acknowledge and agree that all share-related numbers contained
      in this Agreement shall be adjusted to take into account any share split, share dividend or similar event effected with respect to the Common Stock.

   
  

     

   
  15.            Entire Agreement; Amendment; Severability; Waiver.  This Agreement (including all schedules (as amended
      pursuant to this Agreement) and exhibits attached hereto and Placement Notices issued pursuant hereto) constitutes the entire agreement and supersedes all other prior and contemporaneous agreements and undertakings, both written and oral, among the
      parties hereto with regard to the subject matter hereof. Neither this Agreement nor any term hereof may be amended except pursuant to a written instrument executed by the Company and the Agent; provided, however, that Schedule
          2 of this Agreement may be amended by either party from time to time by sending a notice containing a revised Schedule 2 to the other party in
      the manner provided in Section 12 and, upon such amendment, all references herein to Schedule 2 shall automatically be deemed to refer to such amended Schedule 2.  In the event that any one or more of the provisions contained herein, or the application thereof in any circumstance, is held invalid, illegal or
      unenforceable as written by a court of competent jurisdiction, then such provision shall be given full force and effect to the fullest possible extent that it is valid, legal and enforceable, and the remainder of the terms and provisions herein shall
      be construed as if such invalid, illegal or unenforceable term or provision was not contained herein, but only to the extent that giving effect to such provision and the remainder of the terms and provisions hereof shall be in accordance with the
      intent of the parties as reflected in this Agreement.  No implied waiver by a party shall arise in the absence of a waiver in writing signed by such party. No failure or delay in exercising any right, power, or privilege hereunder shall operate as a
      waiver thereof, nor shall any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any right, power, or privilege hereunder.

   
  

     

   
  
    
      


  

  16.            GOVERNING LAW AND TIME; WAIVER OF JURY TRIAL. THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO THE PRINCIPLES OF CONFLICTS OF LAWS THAT WOULD RESULT IN THE APPLICATION OF ANY LAW
        OTHER THAN THE LAWS OF THE STATE OF NEW YORK. SPECIFIED TIMES OF DAY REFER TO NEW YORK CITY TIME. EACH PARTY HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING
        ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY.

   
  

     

   
  17.            Consent to Jurisdiction. Each party hereby irrevocably submits to the exclusive jurisdiction of the U.S.
      District Court for the Southern District of New York or, if that court does not have subject matter jurisdiction, in any state court sitting in the City of New York, Borough of Manhattan, for the adjudication of any dispute hereunder or in connection with any of the transactions contemplated hereby.

   
  

     

   
  18.            Construction.

   
  

     

   
  (a)            The section and exhibit headings herein are for convenience only and shall not affect the construction hereof.

   
  

     

   
  (b)            Words defined in the singular shall have a comparable meaning when used in the plural, and vice versa.

   
  

     

   
  (c)            The words “hereof,” “hereto,” “herein” and “hereunder” and words of similar import, when used in this Agreement, shall refer to this Agreement as a whole and not to any particular
      provision of this Agreement.

   
  

     

   
  (d)            Wherever the word “include,” “includes” or “including” is used in this Agreement, it shall be deemed to be followed by the words “without limitation.”

   
  

     

   
  (e)            References herein to any gender shall include each other gender.

   
  

     

   
  (f)            References herein to any law, statute, ordinance, code, regulation, rule or other requirement of any governmental authority shall be deemed to refer to such law, statute,
      ordinance, code, regulation, rule or other requirement of any governmental authority as amended, reenacted, supplemented or superseded in whole or in part and in effect from time to time and also to all rules and regulations promulgated thereunder.

   
  

     

   
  19.            Permitted Free Writing Prospectuses. Each of the Company and the Agent represents, warrants and agrees
      that, unless it obtains the prior written consent of the other party, which consent shall not be unreasonably withheld, conditioned or delayed, it has not made and will not make any offer relating to the Placement Shares that would constitute an
      issuer free writing prospectus, or that would otherwise constitute a free writing prospectus (as defined in Rule 405), required to be filed with the Commission. Any such free writing prospectus consented to by the Agent or by the Company, as the case
      may be, is hereinafter referred to as a “Permitted Free Writing Prospectus.”  The Company represents and warrants that it has treated and agrees that it will
      treat each Permitted Free Writing Prospectus as an issuer free writing prospectus, and that it has complied and will comply with the requirements of Rule 433 applicable to any Permitted Free Writing Prospectus, including timely filing with the
      Commission where required, legending and record keeping.

   
  

     

   
  
    
      


  

  20.            Absence of Fiduciary Relationship.  The Company acknowledges and agrees that:

   
  

     

   
  (a)            the Agent has been retained to act as sales agent in connection with the sale of the Placement Shares, the Agent has acted at arms’ length and no fiduciary or advisory
      relationship between the Company or any of its respective affiliates, stockholders (or other equity holders), creditors or employees or any other party, on the one hand, and the Agent, on the other hand, has been created in respect of any of the
      transactions contemplated by this Agreement, irrespective of whether the Agent has advised or is advising the Company on other matters, and the Agent has no duties or obligations to the Company with respect to the transactions contemplated by this
      Agreement except the obligations expressly set forth herein;

   
  

     

   
  (b)            the Company is capable of evaluating, and understanding and understands and accepts, the terms, risks and conditions of the transactions contemplated by this Agreement;

   
  

     

   
  (c)            neither the Agent nor its affiliates have provided any legal, accounting, regulatory or tax advice with respect to the transactions contemplated by this Agreement and it has
      consulted its own legal, accounting, regulatory and tax advisors to the extent it has deemed appropriate;

   
  

     

   
  (d)            the Company has been advised and is aware that the Agent and its affiliates are engaged in a broad range of transactions which may involve interests that differ from those of the
      Company and that the Agent and its affiliates have no obligation to disclose such interests and transactions to the Company by virtue of any fiduciary, advisory or agency relationship or otherwise; and

   
  

     

   
  (e)            the Company waives, to the fullest extent permitted by law, any claims it may have against the Agent or its affiliates for breach of fiduciary duty or alleged breach of fiduciary
      duty in connection with the transactions contemplated by this Agreement and agrees that the Agent and its affiliates shall have no liability (whether direct or indirect) to the Company in respect of such a fiduciary claim or to any person asserting a
      fiduciary duty claim on behalf of or in right of the Company, including stockholders (or other equity holders), creditors or employees of the Company.

   
  

     

   
  21.            Recognition of the U.S. Special Resolution Regimes.  In the event that the Agent is a Covered Entity and
      becomes subject to a proceeding under a U.S. Special Resolution Regime, the transfer from the Agent of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as the transfer would be effective
      under the U.S. Special Resolution Regime if this Agreement, and any such interest and obligation, were governed by the laws of the United States or a state of the United States.

   
  

     

   
  In the event that the Agent is a Covered Entity and the Agent or a BHC Act Affiliate of the Agent becomes subject to a
    proceeding under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against the Agent are permitted to be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special
    Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United States.

   
  

     

   
  For purposes of this Agreement, (A) “BHC Act Affiliate” has the meaning assigned to the term “affiliate” in, and shall
    be interpreted in accordance with, 12 U.S.C. § 1841(k); (B) “Covered Entity” means any of the following: (i) a “covered entity” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 252.82(b); (ii) a “covered bank” as that term is
    defined in, and interpreted in accordance with, 12 C.F.R. § 47.3(b); or (iii) a “covered FSI” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 382.2(b); (C) “Default Right” has the meaning assigned to that term in, and shall
    be interpreted in accordance with, 12 C.F.R. §§ 252.81, 47.2 or 382.1, as applicable; and (D) “U.S. Special Resolution Regime” means each of (i) the Federal Deposit Insurance Act and the regulations promulgated thereunder and (ii) Title II of the
    Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder.

   
  

     

   
  
    
      


  

  22.            Counterparts.  This Agreement may be executed in two or more counterparts, each of which shall be deemed an
      original, but all of which together shall constitute one and the same instrument. Delivery of an executed Agreement by one party to the other may be made by facsimile or electronic transmission. Counterparts may be delivered via facsimile, electronic
      mail (including any electronic signature covered by the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act, the Electronic Signatures and Records Act or other applicable law, e.g., www.docusign.com) or other transmission method and
      any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.

   
  

     

   
  23.            Use of Information. The Agent may not provide any information gained in connection with this Agreement and the transactions contemplated by this Agreement, including due diligence, to any third party other than
      its legal counsel advising it on this Agreement and the transactions contemplated by this Agreement unless expressly approved by the Company in writing.

   
  

     

   
  24.            Agent’s Information. As used in this Agreement, “Agent’s Information” means solely the following information in the Registration Statement and the Prospectus: the eighth paragraph under the heading “Plan of Distribution” in the Prospectus Supplement.

   
  

     

   
  All references in this Agreement to the Registration Statement, the Prospectus or any amendment or supplement to any of
    the foregoing shall be deemed to include the copy filed with the Commission pursuant to EDGAR.  All references in this Agreement to financial statements and schedules and other information that is “contained,” “included” or “stated” in the Registration
    Statement or the Prospectus (and all other references of like import) shall be deemed to mean and include all such financial statements and schedules and other information that is incorporated by reference in the Registration Statement or the
    Prospectus, as the case may be.

   
  

     

   
  All references in this Agreement to “supplements” to the Prospectus shall include any supplements, “wrappers” or
    similar materials prepared in connection with any offering, sale or private placement of any Placement Shares by the Agent outside of the United States.

   
  

     

   
  [Remainder of Page Intentionally Blank]

   
  

     

   
  
    
      


  

  If the foregoing correctly sets forth the understanding between the Company and the Agent, please so indicate in the
    space provided below for that purpose, whereupon this letter shall constitute a binding agreement between the Company and the Agent.

   
  

     

   
  

     

   
  	 	
          Very truly yours,

        	 
	 	 	 	 
	 	
          INSMED INCORPORATED

        
	 	 	 	 
	 	
          By:

        	
          /s/ Sara M. Bonstein

        
	 	 	
          Name: 

             

        	 Sara M. Bonstein
	 	 	
          Title:   

             

        	 Chief Financial Officer
	 	 	 	 
	 	
          ACCEPTED as of the date first-above written:

        
	 	 	 	 
	 	
          SVB LEERINK LLC

        
	 	 	 	 
	 	
          By:

        	
          /s/ Peter M. Fry

        
	 	 	
          Name: 

             

        	 Peter M. Fry
	 	 	
          Title:   

             

        	 Head of Alternative Equities


   
  

     

   
  

     

   
  
    
      


  

  SCHEDULE 1

   
  

     

   
  FORM OF PLACEMENT NOTICE

   
  

     

   
  	
          From:

        	
          [                                     ]

        
	 	
          [TITLE]

        
	 	
          Insmed Incorporated

        
	
          Cc:

        	
          [                                     ]

        
	
          To:

        	
          SVB Leerink LLC

        
	
          Subject:

        	
          SVB Leerink—At the Market Offering—Placement Notice

        


   
  

     

   
  Ladies and Gentlemen:

   
  

     

   
  Pursuant to the terms and subject to the conditions contained in the Sales Agreement, dated [●], 202__ (the “Agreement”), by and between Insmed Incorporated, a Virginia corporation (the “Company”), and
    SVB Leerink LLC (“SVB Leerink”), I hereby request on behalf of the Company that SVB Leerink sell up to [●] shares of common stock, $0.01 par value per share, of
    the Company (the “Shares”), at a minimum market price of  $     per share[; provided
    that no more than [  ] Shares shall be sold in any one Trading Day (as such term is defined in Section 3 of the Agreement)].  Sales should begin [on the date of this Placement Notice] and end on [DATE] [until all Shares that are the subject of this
    Placement Notice are sold].

   
  

     

   
  
    
      


  

  SCHEDULE 2

   
  

     

   
  Insmed Incorporated

   
  

     

   
  William H. Lewis

  

   
  Christine Pellizzari

   
  Sara Bonstein

   
  

     

   
  SVB Leerink

   
  

     

   
  Dan Dubin

   
  Sean Pitt

   
  atm@svbleerink.com

   
  

     

   
  
    
      


  

  SCHEDULE 3

   
  

     

   
  Compensation

   
  

     

   
  The Company shall pay SVB Leerink compensation in cash equal to 3.0% of the gross proceeds from the sales of Placement Shares pursuant to
    the terms of the Sales Agreement of which this Schedule 3 forms a part.

   
  

     

   
  
    
      


  

  Exhibit 7(l)

   
  

     

   
  OFFICERS’ CERTIFICATE

   
  

     

   
  Each of [●], the duly qualified and appointed Chief Executive Officer of Insmed Incorporated, a Virginia corporation (the “Company”), and [●], the duly qualified and appointed Chief Financial Officer of the Company, does hereby certify in his or her respective capacity and on behalf of
    the Company, pursuant to Section 7(l) of the Sales Agreement, dated [●], 2021 (the “Sales Agreement”), by and between the Company and SVB Leerink LLC, that,
    after due inquiry, to the best of the knowledge of the undersigned:

   
  

     

   
  (i)            The representations and warranties of the Company in Section 6 of the Sales Agreement (A) to the extent such representations and warranties are subject to qualifications and
      exceptions contained therein relating to materiality or material adverse effect, are true and correct on and as of the date hereof with the same force and effect as if expressly made on and as of the date hereof (except that those representations and
      warranties that address matters only as of a particular date were true and correct as of such date), and (B) to the extent such representations and warranties are not subject to any qualifications or exceptions relating to materiality or material
      adverse effect, are true and correct in all material respects as of the date hereof as if made on and as of the date hereof with the same force and effect as if expressly made on and as of the date hereof (except that those representations and
      warranties that address matters only as of a particular date were true and correct in all material respects as of such date).

   
  

     

   
  (ii)            The Company has complied with all agreements and satisfied all conditions on its part to be performed or satisfied pursuant to the Sales Agreement at or prior to the date hereof.

   
  

     

   
  (iii)            The maximum amount of Placement Shares that may be sold pursuant to the Sales Agreement has been duly authorized by the Company’s board of directors or a duly authorized committee
      thereof pursuant to a resolution or unanimous written consent in accordance with the Company’s Articles of Incorporation, as amended, Amended and Restated Bylaws and applicable law.

   
  

     

   
  Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Sales Agreement.

   
  

     

   
  
    
      


  

  IN WITNESS WHEREOF, each of the undersigned, in such individual’s respective capacity as Chief Executive Officer or
    Chief Financial Officer of the Company, has executed this Officers’ Certificate on behalf of the Company.

   
  

     

   
  

     

   
  	 	
          By:

        	 
	 	 	
          Name:

        
	 	 	
          Title: Chief Executive Officer

        
	 	 	
          Date:

        
	 	 	 
	 	 	 
	 	 	 
	 	
          By:

        	 
	 	 	
          Name:

        
	 	 	
          Title: Chief Financial Officer

        
	 	 	
          Date:

        


   
  

     

   
  
    [Company Signature Page to Officers’ Certificate]